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“My psychiatrist advised that I start with ECT, well, I don’t know, 
it probably won’t work for me, and I am already quite forgetful”
Approximately 4.4% of the population worldwide is suffering from depression.1 The 
symptoms of depression among which depressed mood, anhedonia, feelings of 
worthlessness, and suicidal ideation, are often recurrent and cause severe discomfort.2 
During the last decades, depression was ranked as one of the top leading causes of 
global disease burden.3 In older age (55-74 years), the prevalence of depression tends 
to be higher 1 and older patients are more at risk of developing a chronic or recurrent 
depression than younger patients.4–7 Late-life depression is associated with cognitive 
impairment, comorbid medical illness and increased risk of mortality.8–10 Moreover, a 
study in the United States among older persons showed an increase of nearly 50% in 
healthcare costs for older persons with depression compared to older persons without 
depression.11 Hence, the need for effective treatment is high, especially in older persons. 
It is well known that a large number of patients does not respond to pharmacotherapy 
or psychotherapy.12,13 Treatments using non-invasive brain stimulation such as electro- 
convulsive therapy (ECT) and transcranial magnetic stimulation (TMS) are therefore 
needed. Whereas studies on the efficacy of TMS for depression are growing, the 
effectiveness of ECT is already well established. It was demonstrated that ECT is 
more effective than other antidepressant treatments14,15: the overall remission rates 
of ECT range between 48 % and 66 %16–18 for treatment resistant and non-treatment 
resistant depression, respectively. In comparison, the remission rate for antidepressant 
medication in older depressed patients lies around 37%.13 
ECT uses an electrical current to induce an epileptic seizure of at least 20 seconds in 
duration (with a maximum of three minutes). During the procedure, patients receive an 
anaesthetic and muscle relaxant causing them to be asleep for five to ten minutes. ECT 
is applied twice or three times per week and a course of treatment takes an average of 
eight to 12 sessions.19 In case of catatonia or suicidality, ECT can be administered daily, 
to induce a rapid response.20 The picture below shows a typical ECT setup including a 
patient, ECT device, recording EEG and stimulating electrodes. The electrodes can 
be placed either right unilateral (RUL) or bilateral (BL) which means that one or two 
hemispheres of the brain are stimulated. Cognitive side-effects are lower in RUL, whereas 
the effectiveness may be higher in BL ECT.14,16
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Despite its effectiveness, ECT is largely underused as a treatment for depression: merely 
1.0% of all depressed patients receive ECT in the Netherlands.21 The ECT administration 
rate, that is, the number of ECT administrations per 10.000 population per year, is used 
to compare ECT administration between countries. Compared to other countries the 
ECT administration rate in the Netherlands is low: 9.3 sessions per 10.000 inhabitants22 
compared to 11.2 sessions per 10.000 inhabitants worldwide.23,24 Other European 
countries share these low ECT administration rates25–28 and for example, in England, the 
use of ECT has declined over the past years.29 
One contributing factor to these low numbers is that in many countries ECT is 
recommended in depressed persons only after two trials of antidepressants have 
failed20 also defined as treatment resistant depression. Another factor is the remaining 
stigma around ECT30 and the fear of side effects31 not only in patients but also in 
practitioners. To improve the use of ECT and to get a more personalized depression 
treatment, further insight into which patients may benefit from ECT and which patients 
have the least risk of developing side effects is needed. 




Identification of markers associated with remission of depression could improve patient 
selection for ECT and improve remission rates. Years of ECT research have led to a set of 
clinical markers of patients most likely to respond to ECT, that is, older age, more severe 
depression, presence of psychotic features and less previous trials of pharmacotherapy 
failure17,18,32,33. As these markers have a low effect size, identifying additional (biological) 
markers is essential to further develop targeted treatment.34 In this part of the thesis, we 
explore potential biomarkers of interest.
Immune response and neuroplasticity
First, ECT is thought to induce an initial immune activation followed by a downregulation 
(or normalization) of the immune system.35 Depression itself is associated with elevated 
concentrations of inflammatory markers36–40 and a decrease in inflammatory cytokine 
levels after treatment is associated with treatment response.41,42 Therefore, in this thesis, 
inflammatory markers are further investigated for their potential function as markers 
of ECT outcome. Marker selection was based on their relevance in previous studies on 
inflammation and depression. C-reactive protein (CRP) is most widely used as a clinical 
marker for inflammation43 and is often (in 30-50%) found elevated in depressed patients.39 
Both interleukin-6 (IL-6) and Tumour Necrosis Factor-alpha (TNF-α) are widely used in 
psychiatric research as potential biomarkers involved in depression.44–46 Interleukin-10 
(IL-10) is an anti-inflammatory cytokine47 with strong deactivating properties of the 
inflammatory host response in case of excessive inflammation.48 IL-10 is able to inhibit 
the production of proinflammatory cytokines such as IL-6 and TNF-α.47 
Second, neurotrophic effects may play a part in ECTs working mechanism as volume 
increases in the anterior cingulate cortex have been observed after ECT.49 In addition, 
it is thought that neuroplasticity is disrupted in depression.50–52 S100 calcium-binding 
protein (S100B) is a protein that is expressed by astrocytes and oligodendrocytes. It has 
various functions in neuronal plasticity and apoptosis and can be used as a marker of 
neuroplasticity.53 In this thesis, S100B is included as a potential biomarker of treatment 
outcome. 
White matter hyperintensities
In addition, as previously described, older persons have a higher risk of developing 
chronic depression. It is known that apathetic symptoms can persist after depression 
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treatment54 and that they can lead to a diminished quality of life.55 Despite the difficulty 
of disentangling depressive symptoms like anhedonia from apathetic symptoms like a 
lack of motivation56, apathy is thought to be an independent syndrome.54,57 Small vessel 
disease - in brain imaging indicated by white matter hyperintensities - is increasingly 
suggested as a contributing factor to apathy58–60 and is also more prevalent in late-life 
depression.61 In this thesis, we examine depressive symptoms and apathy after a course 
of ECT. We explore whether patients with white matter hyperintensities are prone to 
developing persistent apathy and hence, a more unfavourable treatment course. 
PART II
Biomarkers and cognition
As mentioned above, only a small number of depressed patients receive ECT. It is thought 
that the stigma surrounding ECT and the fear of side effects have contributed to the 
reluctance to ECT: ECT-related anxiety is found in 47% – 75% of patients eligible for ECT 
treatment.31,62,63 Apart from the mild transient side effects such as nausea, headache and 
myalgia, (transient) cognitive side effects can occur after ECT.64 
The cognitive side effects of ECT can be divided into three groups: postictal confusion, 
anterograde amnesia and retrograde amnesia. Postictal confusion frequently occurs 
after a single ECT session and it manifests as transient (minutes to hours) deficits in 
attention, memory and orientation.64 Anterograde amnesia is the inability to create new 
memories. During a course of ECT patients often experience anterograde amnesia, for 
example, they will not remember some visits of doctors and family members. Retrograde 
amnesia means loss of memory of historical events. For example, some patients will, 
after a course of ECT, not be able to remember certain memories from the past: mostly 
from nonpersonal events and events that have occurred in the six months previous to 
ECT.65 Retrograde amnesia is probably the most debilitating cognitive side effect of ECT.
Current known risk factors for lower cognitive functioning during and after ECT are 
poor baseline cognitive functioning and smaller hippocampal volume.64,66,67 At present, 
it is impossible to identify which persons will experience cognitive side effects. Being 
able to recognize which patients are more prone to develop cognitive side effects is of 
clinical interest as it may lower fear for ECT and it may assist in developing strategies to 
minimize cognitive side effects. In this thesis, we examine cognitive functioning prior to, 
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during and after a course of ECT. We explore whether biological markers can assist in 
discovering which patients are more likely to experience cognitive side effects. At 
present, the mechanism behind cognitive impairment during ECT is unknown. Delirium 
is a syndrome characterized by a decline in cognitive functioning caused by an 
organic process. We have learned from delirium research that inflammation, endocrine 
abnormalities, and oxidative stress outside of the brain can lead to disturbances in 
cognitive functioning by interacting with degenerative changes inside of the brain.68,69 
In line with these findings, we hypothesize that patients with higher levels of peripheral 
inflammation experience lower cognitive functioning during and after ECT. In addition, 
the previously mentioned white matter hyperintensities – a degenerative change of the 
brain - are more common with advancing age.70 Meta-analysis has found an association 
between white matter hyperintensities and progressive cognitive impairment.71 
Therefore, we want to look closer at white matter hyperintensities and their role in 
inflammation and cognition after ECT. 
Aims and outline
This thesis aims to extent current knowledge on biomarkers in ECT-treatment in order to 
contribute to future personalized treatment of late-life depression. The first part aims to 
explore the pattern of biomarkers during a course of ECT and to explore the association 
between biological markers and treatment outcome. The second part aims to examine 
the association between inflammatory markers, cognitive functioning and white matter 
hyperintensities.
Chapter 2 examines the association between S100B and responsiveness to ECT. This 
chapter further concentrates on whether S100B reflects a state marker of depression. 
Chapter 3 examines the association between CRP, IL-6, IL-10, TNF-α and remission of 
depression. It further explores time to remission and speed of decline of depressive 
symptoms. In Chapter 4, the pattern of inflammatory markers throughout the course of 
ECT is examined. The pattern is compared between remitters, non-remitters, responders 
and non-responders. In Chapter 5 the persistence of apathy after ECT is examined in 
relation to white matter hyperintensities. 
Chapter 6 explores whether baseline inflammatory biomarkers are associated with 
cognitive functioning prior to, during and after a course of ECT. Chapter 7 
examines whether this association is different for patients with or without white matter 
hyperintensities. Finally, the clinical relevance of the findings, future implications and 
recommendations for future research are described in Chapter 8.
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All chapters are based on data from the Mood Disorders in Elderly treated with 
Electroconvulsive Therapy (MODECT) naturalistic and longitudinal cohort study.72 
Between 2011 and 2013, 110 older patients (> 55 years) with a depressive disorder, all 
referred for ECT, were recruited in two tertiary psychiatric hospitals (GGZ inGeest, 
Amsterdam, the Netherlands and University psychiatric centre, KU Leuven, Belgium). 
Patients with a DSM-IV diagnosis other than a unipolar depressive disorder were 
excluded as well as patients with a history of a neurological illness including dementia, 
Parkinson’s disease and stroke. The mean age of the sample was 73.0 ± 8.5 years 
and 66.4% were women. In 30.0% of patients, ECT was indicated because of life-threatening 
symptoms such as refusal of food and fluids or suicidality. More than half of the 
sample (58.2%) received ECT after previous pharmacotherapy resistance. Patients 
received ECT twice weekly according to Dutch guidelines.20 ECT was continued until 
remission was reached (MADRS score < 10) or until no further improvement was seen for 
two consecutive weeks after a minimum of six unilateral and six bilateral ECT sessions. 
The response rate (50% improvement or more in MADRS score) was 78.2% and the 
remission rate was 66.4% after a mean number of 11.7 ± 5.4 ECT sessions. 
Before the start of ECT, baseline data were collected including demographics, physical 
comorbidities, medication use, depression severity, cognitive functioning, blood samples 
and magnetic resonance imaging (MRI). The mean depression severity was 33.6 ± 8.6 
(severe depression) as measured with the Montgomery Åsberg Depression Rating Scale 
(MADRS). During ECT, information on depression severity, cognitive functioning and 
apathy was collected weekly. Blood samples were repeated after six ECT sessions and 
one week after finishing a course of ECT. 
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Increasing evidence suggests that glial mediated disruption of neuroplasticity contributes 
to depression. S100 calcium-binding protein B (S100B) promotes neuronal protection in 
nanomolar concentrations. Studies on its possible role a a treatment outcome marker in 
affective disorders are limited. Recent evidence suggests a putative role for S100B as a 
state marker of illness activity as it is found elevated in episodes of major depression. The 
aim of this study was to investigate whether higher S100B is associated with favourable 
treatment outcome following electroconvulsive therapy (ECT) and to further explore 
whether S100B reflects a state marker of depression activity.
Methods 
Serum S100B samples, at baseline and post-ECT and clinical assessments including 
Montgomery Åsberg Rating scales were collected in 91 older depressed patients (mean 
age: 73.0 years), referred for ECT. Change in pre- and post-ECT S100B was compared 
between remitters and nonremitters. Logistic and Cox regression analyses were used to 
determine whether S100B was associated with remission of depression. 
Results 
Patients with S100B levels in the intermediate tertile, that is, between 33 ng/L and 53 
ng/L, had higher odds on remission, odds ratio: 5.5 (95%Confidence Interval (CI): 1.55-
19.20, p = <0.01), and were more likely to remit from depression over time, hazard ratio: 
1.96 (95%CI: 1.04-3.72, p = 0.04), compared with patients in the lowest tertile. There was 
no significant decrease in levels of S100B after ECT in both remitters and nonremitters. 
Conclusion 
Our findings demonstrate that patients with higher S100B levels at baseline were more 
likely to remit from depression suggesting an association between higher S100B and 
responsiveness to ECT. Next, S100B levels do not decrease after remission, suggesting 
S100B is not a state marker of depression. S100B is not capable of predicting treatment 
outcome by itself, further research may combine outcome markers. 
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INTRODUCTION
Unipolar depression is a severe mental illness with impact on cognitive and social 
functioning as well as quality of life.1 Despite various treatment options available, a 
significant number of patients remain symptomatic. Hence, over the past years research 
has focused on finding putative predictors of treatment outcome. Possible markers 
including Brain Derived Neurotrophic Factor (BDNF), c-reactive protein (CRP), 
inflammatory cytokines and cortisol have been examined in previous studies, both in 
antidepressant treatment and electroconvulsive therapy (ECT).2–5
One protein of potential interest that seems to be involved in major depression is the 
S100 calcium-binding protein B (S100B).6–8 This glial protein is located in the cytoplasm 
and nucleus of astrocytes and adipocytes exerting several intra- and extracellular 
functions. Intracellular, it has a regulatory role where it can stimulate cell proliferation 
and inhibit apoptosis and cell differentiation.9 Extracellular effects of S100B are dose 
dependent. In the physiologic, nanomolar concentration range, S100B is thought to 
exert neurotrophic activity promoting neurite extension and protecting neuronal cells10,11, 
whereas in micromolar concentrations (≥ 500 nM/L) S100B contributes to cell injury and 
increases neuroinflammation by activating microglia.9,11 In addition, S100B is sometimes 
regarded as a marker for blood-brain barrier (BBB) permeability as it is found elevated in 
studies regarding BBB disruption.12,13
To date, the role of S100B in depression remains unclear. Previous studies examined 
S100B as a biomarker of treatment outcome. These studies suggest higher levels of 
serum S100B as a favourable feature in the course of disease. Higher baseline levels 
of S100B were associated with favourable ECT response in two studies14,15 and in four 
other studies a better antidepressant treatment response in depressed patients with 
higher levels of S100B was reported.16–19 In addition, a putative role for S100B as a state 
marker of illness activity has been suggested, based on elevated S100B levels that are 
consistently observed in major depression.6,20 Notwithstanding the limited number of 
studies and small sample sizes, these results are promising and challenge us to further 
elucidate the association between S100B and depression. 
Because of the high remission rates following ECT compared with antidepressant 
medication21,22, we aim to investigate whether higher S100B is associated with remission 
of depression after treatment with ECT. Next, we aim to further explore whether S100B 
reflects a state marker of depression activity by monitoring levels pre-ECT compared with 
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post-ECT and investigating the association between S100B and severity of depression. 
Based on previous findings14,15, we hypothesize that higher levels of S100B are associated 
with a favourable ECT outcome. Furthermore, if S100B is a state marker of depression, 
we expect a decline in S100B levels in remitted patients. The standardized procedures 
for the inclusion and treatment of patients in the Mood Disorders in Elderly treated with 
Electroconvulsive Therapy (MODECT) multicentre study, as well as for the collection and 
storage of serum samples, give us the unique opportunity to study S100B and treatment 
outcome in a relatively large sample of depressed patients treated with ECT. 
METHODS
Subjects
The data for this study was derived from the multicentre study ‘Mood Disorders in 
Elderly treated with Electroconvulsive Therapy’ (MODECT) as described earlier.23 
MODECT included 110 patients, aged > 55 years, who fulfilled the DSM-IV criteria for 
major depression24, as assessed by the Mini International Neuropsychiatric Interview 
(MINI)25, and who were referred for ECT. All patients were recruited from an inpatient 
population at the department of Old Age Psychiatry of GGZ inGeest, Amsterdam, the 
Netherlands and the University Psychiatric Center KU Leuven, Belgium. Patients with 
a DSM-IV diagnosis of bipolar disorder or schizoaffective disorder were excluded from 
the study. Moreover, patients with established dementia or a major neurological illness 
were excluded. Written consent was obtained from all patients. The study protocol was 
approved by the ethical review board of the Amsterdam UMC and UPC Leuven and 
adhered the declaration of Helsinki. 
S100B
Serum samples were collected between 07h30 and 09h30 and were stored at 
–85°C until assayed for S100B levels. Serum S100B values were determined using a 
chemiluminescence immunoassay (Elecsys ® S100) run on the Cobas 6000 analyser 
system (Roche Diagnostics), at the Endocrinology laboratory of the Department of 
Clinical Chemistry of the University Medical Center, VUmc, in Amsterdam, the 
Netherlands. Baseline and follow up samples of a patient were always assayed in 1 run. 
The S100B test had a measurement range from 0.005 μg/L to 39 μg/L. To facilitate 
interpretation, we present S100B in ng/L. In every run and after each system calibration, 
control samples of different concentrations were included, and results plotted in the 
QC system. Intra-assay variation (CV) was 1.3% and the inter-assay CV 4.6%. As the 
relation between levels of S100B and remission of depression was not linear, 
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serum S100B data was divided in categories. We additionally performed calculations to 
determine study size using Altman’s nomogram.26,27 We used an 80% probability of 
detecting differences in remission at a 5% significance level. The standardized 
difference was calculated using data from one earlier study investigating the relation 
between S100B and treatment outcome in depressed patients.18 The calculations showed 
that it was sufficient to have 30 patients. We used tertiles (lowest tertile: ≤ 32 ng/L, 
intermediate tertile: 33 – 53 ng/L, highest tertile: ≥ 54 ng/L) in order to minimalize loss 
of information and to maintain sufficient group size (n ≈ 30). To evaluate the robustness 
of these findings, we repeated the analyses for dichotomized values of S100B, cut-off 
median value (low S100B: < 42 ng/L, high S100B: ≥ 42 ng/L). 
Measures
Data were available at baseline (T0) and one week post-ECT (T1). Patients with missing 
values in depression severity at T0 and T1 and patients with missing S100B values 
on T0 were excluded from analyses (n = 16). Attrition was differential with respect to 
inclusion site, with a higher number of persons with missing serum samples in 
Amsterdam, The Netherlands. Attrition was not associated with age, sex, and depression 
severity. Depressive symptoms were assessed using the Montgomery-Åsberg 
Depression Rating Scale (MADRS)28, assessed prior to ECT, weekly during ECT and one 
week after ECT was ended (post-ECT). A semi-structured interview was performed to 
retrieve socio-demographics and clinical characteristics and included age, sex, body 
mass index (BMI), the use of antidepressant medication during ECT, and presence of 
cardiovascular diseases and malignant neoplasms. Several depression characteristics 
were examined, including depression severity (total MADRS score), treatment resistance, 
presence of psychotic symptoms, age of onset, duration of index episode of depression 
and recurrence of depression. Treatment resistance was defined as at least one trial 
with a score on the Antidepressant Treatment History Form (ATHF) of ≥ 3, representing 
adequate dose and duration of the trial.29 Considering differences in definitions, an 
elaboration on the definition of medication resistance is available in the supplemental 
material. The presence of psychotic symptoms was assessed by a psychiatrist according 
to DSM-IV criteria24, and confirmed by the MINI.25 Early onset is defined as first episode 
before 55 years of age. Self-report was used for duration of index episode (in months) 
and recurrence of depression (at least one previous episode of depression). 
ECT procedures
Patients were treated twice weekly with ECT, in accordance with Dutch Guidelines.30 
Seizures were induced by brief-pulse ECT (1.0 ms), administered by the Thymatron 
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System IV (Somatics, LLC, USA) with a maximum stimulus level of 1008 mC. Stimulus 
intensity was determined according to a dose titration protocol. A seizure of less 
than 20 seconds motor activity or less than 25 seconds EEG activity, was considered 
inadequate. Stimulation was changed to bilateral when clinical conditioned worsened 
or after six unilateral ECT sessions without improvement. Treatment was discontinued 
when patients reached remission, defined by a MADRS <1028, or when no further 
improvement was achieved. After discontinuing ECT, the majority of patients received 
antidepressants (n=57/91) and add-on lithium (n=30/91). A small portion of patients 
received maintenance ECT (n=7).
Statistical analysis
All statistical analyses were performed using SPSS version 23. Group differences for 
continuous variables were analysed using independent samples t-tests (for normally 
distributed samples) and Mann-Whitney U tests (for nonnormally distributed values). 
For categorical variables, χ2 tests were used. Normality was examined using visual 
exploration of the data. Outliers (above 3x interquartile range) for S100B at baseline 
(n = 3) were excluded from analysis. Spearman’s test for correlations was used to 
examine correlations between depression severity and S100B. Change scores (delta, Δ) 
of pre- and post-ECT S100B levels and MADRS scores were calculated by subtracting 
T0 from T1. Change scores were accordingly evaluated using Mann-Whitney U test. 
The association of S100B with remission of depression was examined using logistic 
regression analysis. Hazard ratio (HR) was examined using Cox regression analysis, 
with total number of received ECT sessions as time indication. The assumption of 
proportionality of hazard was checked. All analyses were adjusted for age. To develop 
an optimal covariate model from several variables a stepwise procedure was chosen 
for logistic regression. The covariates used for backwards regression analyses were 
depression severity, presence of cardiovascular disease, presence of malignant 
neoplasm, the use of antidepressant medication during ECT, duration of index 
episode, pharmacotherapy resistance, and presence of psychotic symptoms as these are 
suggested in current literature as putative confounders.7,9,11,31,32 To check for 
multicollinearity the variation inflation factors (VIF) were calculated, where a VIF 
of ≥ 2 was considered as an indicator of multicollinearity. 
 S100B and remission  |  33
Table 1. Sociodemographics, somatic morbidity and depression characteristics of the 












73.0 (8.0) 71.8 (7.3) 73.8 (8.7) 73.3 (8.2) 0.6
Women, No. (%) 63 (69.2) 20 (66.7) 22 (71.0) 21 (70.0) 0.9
Baseline MADRS, 
mean (SD)












52 (57.1) 21 (70.0) 17 (54.8) 14 (46.7) 0.2
Number of ECT, 
mean (SD)
11.6 (5.0) 12.9 (6.2) 11.2 (4.7) 10.6 (3.7) 0.2
Somatic morbidity
Cardiovascular 
disease,  No. (%)
22 (24.7) 7 (24.1) 7 (23.3) 8 (26.7) 1
Malignant neo-
plasm, No. (%)
15 (16.9) 5 (17.2) 4 (13.3) 6 (20.0) 0.8
BMI, mean (SD), 
n = 61
23.4 (3.9) 21.8 (3.6) 23.6 (3.6) 24.6 (4.2) 0.11
1 p for trend = 0.01
SD = standard deviation, IQR = inter quartile range, No. = number, MADRS = 




Baseline characteristics of the study population and the distribution across tertiles of 
S100B serum levels are shown in Table 1. The sample consisted of 91 older depressed 
persons, of which 69.2% patients were female, with a mean age of 73.0 years. Patients 
received between 4 and 29 ECT sessions (mean of 11.6 ± 5.0 (Standard Deviation)). The 
majority of patients received unilateral ECT (64.8%). Mean depression severity at baseline 
was 33.7 on the MADRS indicating severe depression. Median S100B at baseline was 
42 ng/L. There were no significant differences between patients with different levels of 
S100B with respect to age, sex, depression severity or duration of treatment. 













42 (46.2) 12 (40.0) 11 (35.5) 19 (63.3) 0.1
Medication 
resistant, No. (%), 




6.0 (10.0) 6.0 (9.3) 6.0 (10.8) 6.0 (7.5) 0.9
Recurrence, 
No. (%)
70 (76.9) 23 (76.7) 25 (80.6) 22 (73.3) 0.8
Early onset, 
No. (%)




42.0 (27.0) 25.0 (7.3) 42.0 (10.0) 70.5 (33.0) <0.01
Post-ECT, 
median (IQR)
40.0 (30.0) 24.5 (14.3) 45.0 (14.5) 60.5 (35.3) <0.01
SD = standard deviation, IQR = inter quartile range, No. = number
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S100B and remission
As shown in Table 2, there is an overall difference between S100B tertiles (p = 0.03) with 
respect to remission rates. Patients in the intermediate tertile (S100B: 33 ng/L - 53 ng/L) 
have higher odds on remission compared with patients in the lower tertile: odds ratio 
(OR) 5.46 (95%Confidence Interval (CI): 1.55-19.20). Confidence intervals are wide as 
expected with a small sample size. Also, patients in the highest tertile (S100B: > 54 ng/L) 
tended to have a higher odd on remission as compared with the lowest tertile, 
although this was not significant: OR 1.25 (95%CI: 0.42-3.74). Presence of psychotic 
symptoms was identified as putative confounder and was therefore included as 
covariate in multivariable analysis. Pharmacotherapy resistance and BMI were also 
identified as putative confounders (p = 0.1 and p < 0.01). However, considering the 
number of missing values (respectively, n = 8 and n = 30) of both covariates, we decided 
to include only presence of psychotic symptoms in multivariable analyses, in order to 
maintain sufficient power. There was no significant multicollinearity between covariates. 
In separate post hoc analysis including pharmacotherapy resistance and BMI as 
covariates (n = 56), a higher odd on remission for patients in the middle tertile compared 
with the lower tertile was found, although not significant: OR 3.76 (95%CI: 0.67-21.11). 
In addition, post hoc analysis showed an association between higher BMI and higher 
levels of S100B, p for trend = 0.01. Post hoc analyses with inclusion of baseline S100B 
outliers (n = 3) did not alter our findings. To test the robustness of our findings, analyses 
were repeated for dichotomized values of S100B, cut-off median value (≥ 42 ng/L), 
however results did not reach significance: OR 1.82 (95%CI: 0.73-4.56). 
Table 2. Association between S100B (ng/L) and remission of depression in logistic 
regression analyses shown for tertiles in older depressed patients treated with ECT. 
Overall difference between tertiles p-value 0.04 for univariate and p-value 0.03 for 
multivariate analysis.
Univariate Multivariate 
OR (95% CI), n = 91 p OR (95% CI), n = 91 p
Lowest Tertile Reference Reference
Intermediate Tertile 4.55 (1.38-15.05) 0.01 5.46 (1.55-19.20) <0.01
Highest Tertile 1.51 (0.54-4.24) 0.4 1.25 (0.42-3.74) 0.7
Multivariate model: adjusted for age, gender and presence of psychotic symptoms
OR = odds ratio, CI = confidence interval
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S100B and time to remission
In both univariate and multivariable Cox regression analyses, patients in the intermediate 
tertile were more likely to remit from depression over time, compared with the lowest 
tertile: HR 1.96 (95%CI: 1.04-3.72). For the dichotomized value of S100B, the HR for 
remission was 1.45 (95%CI: 0.86-2.44). 
S100B as a biomarker
When measuring the predictive values of S100B as a biomarker of treatment outcome a 
sensitivity of 55.7% and specificity of 60.0% was found. The positive predictive value was 
73.9% with a false positive rate of 40.0%. The negative predictive value was 40.0% with a 
false negative rate of 44.3%.
 
No change in S100B between pre- and post-ECT measurement
As shown in Figure 1, there was no statistically significant difference in baseline and 
post-ECT S100B levels between remitters and nonremitters (respectively U = 813, 
p = 0.4 and U = 617.5, p = 0.2). In addition, there was no statistically significant difference 
in delta S100B from baseline to post-ECT between remitters and nonremitters (delta 



















  Remission   Non-Remission
Figure 1. S100B levels at baseline and one week post-ECT between groups of remitters 
and non-remitters in older depressed patients treated with ECT (n = 91).
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S100B in remitted patients was 44 ng/L at baseline and 45 ng/L post-ECT. Two patients 
were excluded from further analysis with a higher than three IQR increase in S100B, 
respectively a change of 618 ng/L and 457 ng/L. 
No association with depression severity
There were no significant associations between baseline S100B and baseline 
MADRS (Spearman: -0.05, p = 0.6), recurrent depression (defined as at least one 
previous episode of depression, Spearman: 0.08, p = 0.4), presence of psychotic 
symptoms (Spearman: 0.12, p = 0.3) and duration of index episode of depression 
(Spearman: -0.09, p = 0.4). 
DISCUSSION
The aim of this study is twofold. First, we aim to determine whether higher S100B is 
associated with remission of depression after treatment with ECT. Second, we 
aim to investigate whether S100B reflects a state marker of depression activity, by 
monitoring change in levels pre- and post-ECT and investigating the association of S100B 
with severity of depression. We therefore assess the glial protein S100B in depression 
in a large cohort of patients treated with ECT. Our study provides evidence that higher 
serum S100B levels are associated with favourable treatment outcome and faster 
remission in response to ECT and demonstrates similarity in S100B levels post-ECT 
compared with pre-ECT in those remitted from depression. These findings are contrary 
to the idea that S100B reflects a state marker of major depression. 
Our findings confirm the association between serum S100B levels and responsiveness 
to treatment. A favourable treatment response to antidepressant medication or ECT in 
depressed patients with higher levels of baseline S100B was demonstrated in multiple, 
albeit small studies, summarized in Table 3.14,15,17–19 All but one16 study suggested 
increased responsiveness to treatment in patients with higher levels of S100B. These 
findings suggest the positive impact of S100B on plasticity processes. One hypothesis 
explaining these results might be that depressed patients suffer from a loss of 
neuroplasticity. The micro inflammation in the brain, initiated by neuronal 
impairment caused by depression15 can result in a compensatory release of S100B, 
counteracting the neurodegenerative mechanisms of major depression. As suggested 
by Rajewska-Rager et al., S100B might have a positive impact on neuroplasticity 
processes20 because of its neuroprotective effect by inducing neuronal growth and 






















































































































































































































































































































































































































































 S100B and remission  |  39
density in glial cells in mood disorders suggesting a disruption in neuroplasticity as 
etiological factor.33–35 In our study, patients in the highest S100B tertile did not have a 
significantly better treatment response compared with the lowest tertile. Although 
patient samples were within the nanomolar range, this may be due to the wide 
distribution of S100B in the highest tertile, as a result of heterogeneity within this 
subsample of patients, and some patients having higher levels of S100B as a result of 
other factors than depression, such as an acute phase reaction.11 The sensitivity and 
specificity of S100B were low suggesting this marker is not eligible as a sole predictor 
of treatment outcome. The additional benefit of combining biomarkers is subject for 
further research. 
Second, there is an ongoing discussion whether higher levels of S100B in patients 
with depression represent a state marker of illness activity as S100B levels are 
consistently found elevated in depressed patients compared with healthy controls.6,7,20 
If S100B were a state marker of depression, its levels would be expected to decrease 
after remission of depression and to be associated with severity of depression. However, 
our study, in line with one small ECT study (n = 11), shows there is no change in S100B 
over the course of ECT in both remitters and nonremitters, see also Table 3. In addition, 
in our study, with a larger study sample, S100B is not associated to depression severity. 
Two other studies describe no change in S100B after treatment with antidepressant 
medication17,18 compared with one study showing reduced S100B levels after 
antidepressant treatment.36 Previous findings are inconsistent on whether S100B levels 
are influenced by severity of symptoms15,17,36,37 or not.16,18 The majority of studies found no 
correlation between depressive symptoms and S100B.6 
Our findings contradict the idea that S100B is a state marker of illness activity and fuel 
the idea that higher levels of S100B are a long-term adaptation of the brain to stress 
associated with depression or is innate contributing to the onset of depression. A 
positive correlation between levels of S100B and stressful activity has been shown in 
physicians on duty as well as in mother and new-born after prolonged labour11,38,39 
establishing the capacity of the brain to adapt, in this case to stressful 
circumstances. In addition, exposure to childhood trauma has been associated to 
higher levels of S100B in adolescents.40 If this hypothesis is confirmed, this brain 
adaptation could on the one hand inflict susceptibility for psychiatric disease as is 
underlined by lower S100B in healthy compared with depressed patients.6,31 On the 
other hand, this adaptation could imply an impact on neuroplasticity processes as 
mentioned above. Additional support for this hypothesis is the fact that an increase 
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of S100B is not selectively found in depression but is also found in patients with 
schizophrenia.41,42 In addition, two studies found evidence that increased S100B levels 
help to restore normal cognitive functioning in depressed patients43,44, strengthening 
the idea that either S100B, or S100B releasing glial cells, have the ability to restore 
impaired processes. It would be interesting to look at cognition in relation to S100B 
in future studies. 
Finally, it should be mentioned that S100B can exert a neurotoxic function as opposed 
to the neurotrophic function described above. Increased serum levels of S100B have 
been attributed to increased permeability through an impaired blood brain barrier (BBB) 
and is used as a biomarker of brain injury in Neurology.11,13 However, recent evidence 
suggests that higher serum S100B levels imply an active S100B release from glial cells 
reflecting neuroplasticity and glial activation rather than release from damaged 
astrocytes45 and should be interpreted as normal passage of S100B to the extracellular 
fluid.13,45,46 Studies in schizophrenia patients support this notion, as increased serum 
levels of S100B coincided with increased glial activation as detected by 
MR-spectroscopy.47 Because the biologic effects of S100B are thought to be 
dose-dependent, the increased concentrations observed in our sample could indicate 
neuronal activation rather than neuronal damage or BBB damage. 
Strengths and limitations
Notably, our findings should be interpreted in the context of the following strengths and 
limitations. To our knowledge, the current study has the largest sample of serum S100B 
in depressed patients referred for ECT. Nonetheless, confidence intervals are wide. Any 
conclusions drawn from these results need to be replicated in a larger sample size. 
Second, the substantial set of clinical data collected from patients allows us to 
adjust for putative confounders. An additional strength is that our study includes a well 
described, rather homogenous sample of severely depressed patients. On the other hand, a 
limitation of this study is that results might not be applicable to younger patients with 
mild or moderate depression. It is shown previously that age may have impact on S100B7, 
therefore age is controlled for in our analyses. In addition, besides brain injury and 
glial activation, there are several other factors known to increase S100B, including heart 
ischemia, melanomas, BMI and the use of serotonergic medication.9,11,32,48 Adjustment 
for ischemic heart diseases, presence of malignancies and the use of antidepressant 
medication during ECT does not alter our results making it less likely to have influenced 
S100B levels in our sample. In addition, S100B levels were determined one week 
after ECT, therefore it is unlikely that treatment received after discontinuing ECT 
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(maintenance ECT or antidepressant medication) has influenced our results. Next, 
post hoc analysis shows a significant upward trend in BMI for higher S100B levels. This 
finding is explained by the well-known association between adipose tissue and levels of 
S100B.48,49 Despite the missing data on BMI, post hoc analysis with the available 
data (n = 56) showed similar results, which suggests a limited effect of BMI on 
the association between S100B and ECT outcome. In line with this, as S100B 
is viewed as a biomarker of brain injury13, one might suspect that ECT-induced 
seizures cause an increase in levels of S100B, limiting any statements on the change 
scores between pre- and post-ECT S100B. However, several studies have shown 
that there is no increase in S100B during the course of ECT and found no 
association between S100B and energy dose or seizure duration16,50,51, suggesting ECT 
does not cause brain injury and thus does not cause an increase in levels of S100B. 
Finally, Yang et al. have shown a positive correlation between levels of S100B and 
number of episodes of depression which might suggest a form of kindling as the brain 
is going through recurrent depressive episodes.31 Therefore, one might expect to 
find higher S100B levels in patients with more previous episodes or a longer 
duration of index episode of depression. The absence of information on the number of 
previous episodes is considered a limitation in this respect. In addition, no 
correlation is found between S100B and index episode duration. However, the 
relative long index episode  duration of the entire sample (mean: six months), 
might explain the absence of this correlation. Future studies should include the 
number of previous episodes and should include both short and long index episode 
duration. 
Future implications
Higher levels of S100B are associated with favourable treatment outcome. Conversely, 
patients with low levels of S100B tend to benefit less from both ECT and antidepressant 
medication. Therefore, further research is needed to unravel treatment strategies for 
these patients. Although not yet studied in depression, a handful of studies regarding 
the effect of S100B on neurogenesis find positive neuroprotective effects of daily S100B 
administration in mice or human cell lines.52–54 Given our findings, increasing the level of 
S100B may contribute to responsiveness to treatment.
Conclusion
This study provides evidence that higher levels of S100B in patients with 
severe depression, treated with ECT, are associated with higher and faster remission 
rates. Serum S100B levels do not decrease upon remission, which makes it less likely 
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that S100B is a state marker for depression. Our findings warrant replication. If 
future studies confirm our findings, higher levels of S100B could, in combination 
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SUPPLEMENTAL MATERIAL
There is no clear definition of treatment resistance. In our paper, the definition of 
Prudic et al. (1996) was used, who have classified medication resistant as at least one 
antidepressant trial of any type with an adequate dose for a minimum of 4 weeks.1 In 
a review of Berlim et al. (2007) another definition is recommended, that is, at least two 
antidepressant trials with adequate dose and duration.2 The distribution of patients 
with medication resistance using the definition of both Prudic et al. and Berlim et al. are 
shown in the table below. 
The number of patients that fall into the medication resistant category is reduced by 
50 percent when using the definition of Berlim et al., however, results from post hoc 
regression analyses are minimally altered.
Supplemental Table. Distribution of treatment resistance using two different criteria 









- Medication resistant 
1 trial, No. (%)
56 (67.5) 14 (53.8) 21 (67.7) 21 (80.8) 0.1
- Medication resistant 
2 trials, No (%)
27 (32.5) 7 (26.9) 11 (35.5) 9 (34.6) 0.8
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INFLAMMATION AND REMISSION 
IN OLDER PATIENTS WITH 





Compelling evidence links elevated C-reactive protein (CRP) and other inflammatory 
markers to poor treatment outcome to antidepressant medication. Little is known about 
the contribution of low-grade inflammation on treatment response to Electroconvulsive 
Therapy (ECT) in severely depressed patients. 
Method
Associations between serum levels of CRP, Interleukin-6, Interleukin-10, Tumour 
Necrosis Factor-α, and remission of depression, time to remission and speed of decline 
of depressive symptoms, were examined in 95 older (mean age: 73.1) depressed patients 
treated with ECT.
Results
Moderately elevated levels of CRP at baseline (3 to 10 mg/L), but no other inflammatory 
markers were associated with higher remission rates. Odds ratio for remission, in those 
with moderately elevated CRP levels was 3.62 (95% confidence interval [CI],1.09-11.97; 
p = 0.04). Time to remission was shorter in those with moderately elevated CRP levels, 
p=0.05. Speed of decline was higher in those patients with moderately elevated CRP 
levels as compared to those with low CRP levels (decline of 3.2 MADRS points per 
administration vs. 2.3 points per administration, p=0.03). Limitations: because of the 
observational design, residual confounding through other lifestyle- or demographic 
factors cannot be ruled out. 
Conclusions
Whereas earlier studies show that low-grade inflammation contributes to poor treatment 
response in those treated with antidepressants, our study provides clues that low-grade 
inflammation does not have such a detrimental effect on the treatment response to ECT. 
This is underscored by our finding that moderately elevated CRP levels were associated 
with increased remission rates in depressed patients treated with ECT. Replication studies 
are warranted.
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INTRODUCTION
Compelling evidence linking depression to systemic inflammation has emerged over the 
last twenty years. Administration of bacterial endotoxin, inducing an inflammatory cytokine 
response in animals and humans, reproduces depression-like “sickness behaviour”, 
such as decreased interest, social withdrawal, insomnia, decreased motor activity and 
anorexia.1–3 Recent meta-analyses of cross-sectional studies showed that elevated levels of 
inflammatory markers in patients, such as interleukin 6 (IL-6) and C-reactive protein (CRP) 
are associated with depression.4–7 Moreover, results from longitudinal studies suggest 
a causal relationship between elevated levels of inflammatory markers and incident 
depressive symptoms8–10, although controversy regarding the role and contribution of 
inflammatory markers on depression still exists.7,11,12
The controversies on the role of inflammatory markers on depression are possibly 
due to differences in the patient samples under study. It is likely that inflammation 
is not generally present in depression but linked to an “inflammatory depression 
subtype”. Several studies repeatedly reported that elevated levels of inflammatory 
markers are associated with later age of onset, comorbid physical illnesses, 
cognitive impairment, reduced motivation, recurrent episodes, and persistence of 
symptoms.13–18 In addition, results from meta-analysis suggested that patients 
with elevated inflammatory markers had more non-response to antidepressant 
medication.15 It is possible that this subgroup of patients with elevated levels of 
inflammatory markers might profit from anti-inflammatory medication as is proposed by 
Lang19 and Miller.20
Among the treatments for depression, electroconvulsive therapy (ECT) is superior 
effective compared with antidepressant medication21, with remission rates 
ranging between 48% and 65% in those with medication-resistant depression.22,23 
Several reviews examined inflammatory markers through the course of ECT. They 
suggest an acute immune response after a single ECT administration followed by 
a decrease in cytokines levels after multiple ECT administrations.24–29 One study 
has examined the predictive effect of inflammatory markers on ECT response 
in depressed patients. Findings from this study showed that elevated 
CRP levels were associated with a reduction of depressive symptoms in 
women (n=15). These findings, although obtained in a study with limited group size, 
fuel the controversy over the role of inflammatory markers on depression.30 
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We studied the effect of ECT on remission, time to remission and speed of decline of 
depressive symptoms in a population of depressed patients with low-grade inflammation. 
Based on previous findings13,15,17, we hypothesize that moderately elevated levels of 
inflammatory markers contribute to poor treatment outcome, not only in those treated 




This study was conducted as part of the Mood Disorders in Elderly treated with 
Electroconvulsive Therapy (MODECT)31, a naturalistic longitudinal cohort study (n=110) 
of patients aged 55 years and older with severe unipolar depression. The authors 
assert that all procedures contributing to this work comply with the ethical standards 
of the relevant national and institutional committees on human experimentation and 
with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving 
patients were approved centrally by the Ethical Review Board of the Amsterdam 
University Medical Centre, and subsequently by the ethical review board of the Leuven 
University Hospital. Written informed consent was obtained from all patients. Patients 
received ECT treatment from two tertiary psychiatric hospitals in the Netherlands 
(GGZ inGeest, Amsterdam) and Belgium (University Psychiatric Centre, KU Leuven) and 
were recruited between 1 January 2011 and 31 December 2013. Patients with a 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis other than 
unipolar depressive disorder were excluded. Also, patients with a major neurological 
illness, including Parkinson disease, stroke, and dementia, were excluded. Fifteen 
subjects were excluded from the analysis, due to missing data regarding biomarkers or 
Montgomery Åsberg Depression Rating Scale (MADRS) scores.32 Age, sex, age of onset 
of depression, baseline MADRS score and the total number of ECT treatments were not 
associated with attrition.
Measurements
Diagnosis of major depressive disorder, according to the DSM-IV, was made by a 
psychiatrist and validated with the MINI International Neuropsychiatric Interview 
(MINI).33,34 The severity of depression was assessed using the MADRS one week before 
and one week post-ECT treatment. For clinical relevance of study results, primary 
outcome measures were remission, defined as a MADRS score of less than ten at two 
consecutive ratings, and time to remission.35 We also determined speed of decline of 
depressive symptoms, defined by reduction of MADRS score relative to the number of 
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ECT administrations. Serum samples were collected one week prior to ECT between 
07h30 and 09h30 and were stored at -85 °C. Samples were assayed between seven and 
43 months after collection. Number of chronic somatic diseases, including cardiovascular 
disease, hypertension, diabetes mellitus, chronic respiratory disease and arthrosis, was 
assessed in a semi-structured interview. Medication-resistance was defined as a history 
of at least one antidepressant trial with a resistance score higher or equal to three 
according to the Antidepressant Treatment History Form (ATHF).36 A trial’s strength on 
the ATHF is rated from one, duration shorter than four weeks, to five, duration longer 
or equal to four weeks with adequate antidepressant dose and lithium augmentation. 
Depression characteristics were defined as medication-resistant, early-onset of 
depression (first episode before 55 years of age), duration of index episode or presence 
of psychotic symptoms (based on the DSM-IV and MINI).33,34 We regarded several 
variables as potential confounders, including socio-demographic variables (sex and age), 
total number of chronic disease, Body Mass Index (BMI), current smoking (yes/no), 
alcohol use (yes/no), and depression characteristics (medication resistance, early onset, 
duration of index episode and presence of psychotic symptoms). 
Inflammatory markers
Serum levels of Interleukin-6 (IL-6), Interleukin-10 (IL-10) and Tumour Necrosis Factor-α 
(TNF-α) were simultaneously determined with a 3-step multiplex digital immunoassay, 
the Simoa Human Cytokine 3-Plex A assay kit (Quanterix; cat.# 101160), using the Simoa 
HD-1 Analyzer and Single Molecule Array (Simoa) technology. Intraassay and interassay 
reproducibility (coefficient of variation (CV), for interassay cv based on data from ten 
runs) were 4.3% and 5.9% for IL-6, 3,9% and 5.3% for IL-10 and 4,2% and 5.3% for TNF-α, 
respectively. Upon thawing, the serum samples were mixed by inverting, spun at 4 °C 
(10’; 10000g), and assayed immediately. As a quality control, samples containing either 
low or high cytokine levels, were included in each plate run. Low grade inflammation 
was defined as levels of inflammatory cytokines above the median. Levels of CRP were 
determined with the High Sensitive (CRPhs) kit (Cobas CRPHA; Cat. No. 04628918 190) 
using the Cobas 6000 module c501 (Roche Diagnostics), which measures complexes 
between CRP in the sample and specific antibodies coupled to latex particles. The 
measurement range of the assay is 0.15 – 20 mg/L (after rerun (diluted sample) up to 
300 mg/L). Two control samples were included in each run. Cytokine and CRP 
determinations were performed at the Clinical Chemistry department of Amsterdam 
UMC, Vrije Universiteit Amsterdam. Low grade inflammation for CRP, that is, moderately 
elevated CRP (cut-off: 3mg/L), was defined in accordance with clinical guidelines from 
the Centres for Disease Control and Prevention and the American Heart Association.37,38 
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CRP values higher than 10 mg/L were excluded from analyses (n=10) to avoid possible 
confounding effects of systemic inflammatory diseases and acute infection.37
ECT procedure
Patients received twice-weekly ECT in accordance with the Dutch guideline for ECT.39 All 
treatments were administered with the Thymatron System IV (Somatics, LLC, Lake Bluff, 
IL, USA) (maximum energy 200%, 1,008 C). The stimulus intensity was determined by 
empirical dose titration; initial seizure threshold x6 for right unilateral ECT and x2.5 for 
bilateral ECT. All patients were treated with brief-pulse ECT (1.0 ms). A course started with 
right unilateral ECT preferably, when clinical condition worsened (i.e. an increase in total 
MADRS scores, presence of debilitating psychotic symptoms, increased suicidality, 
dehydration or weight loss, or when after six unilateral treatments there was no 
clinical improvement according to the judgement of the treating psychiatrist), treatment 
switched to bilateral lead placement. ECT was continued until remission or discontinued 
when patients showed no further improvement in clinical condition during two weeks 
after a minimum of six unilateral and six bilateral ECT administrations. Psychotropic 
medication was discontinued at least one week before ECT or kept stable before ECT and 
during the ECT course if necessary. 
Statistical analyses
IBM SPSS statistics 23 was used for all data analyses. Differences in covariates between 
remitters and non-remitters were tested using Chi-square statistics for categorical 
variables. For continuous variables with a normal distribution, independent t-tests were 
performed. Non-parametric testing was applied for non-normally distributed variables. 
All values of inflammatory markers were skewed to the right, and natural log 
transformed. For clinical purposes all analyses were performed using both continuous 
and dichotomized values of inflammatory markers. Outliers were determined using 1.5x 
IQR after log transformation and were excluded from analyses (n=1, TNF-α). The relation 
between levels of inflammatory markers and remission was assessed using binomial 
logistic regression analyses. No adjustment for multiple testing was made since 
hypotheses were formed on the relation between inflammatory markers and remission 
of depression. A Cox proportional hazards model for time-to-event was used to 
evaluate the association between inflammatory markers and time (number of ECT 
administrations needed) to remission. Variables in model 1 were obtained using 
univariate analyses. Consecutively, in model 2, the following covariates; age, sex, baseline 
MADRS, depression characteristics, number of chronic disease, BMI, smoking and 
alcohol use, were eliminated one by one according to the level of non-significance 
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(backward regression analysis) and included in the model if sustained significant. 
Additionally, multicollinearity was tested using variance inflation factor. We used linear 
regression to determine the effect of CRP levels on speed of decline of depression 
symptoms, adjusted for the above-mentioned covariates. IL-6 and TNF-α values were 
summed up after conversion to a z-score to evaluate if a total sum score had additional 
predictive power (inflammation composite). Regression coefficients in the logistic and 
Cox models were evaluated with a two-sided Wald test. Cohen’s d statistic was used 
to calculate effect sizes.40 Finally, in all multivariable analyses we added age and sex as 
potential confounders.
RESULTS
The mean age of patients was 73.1 years (range 55-92 years). The mean baseline 
MADRS score of the sample was 33.7, indicating severe depression. 65 of 97 (67.7%) of 
patients were identified as remitters. The mean number of ECT treatments was 11.6. 





n = 95 n = 65 n = 30
Socio-demographics
Age, years, mean (SD) 73.1 (8.2) 73.2 (8.2) 72.8 (8.3) -0.19(93), 0.8
Women, No. (%) 65 (68.4) 42 (64.4) 23 (76.7) 1.4(1), 0.2
Level of education, years,
median (IQR), n=83
9.0 (3.0) 9.0 (3.0) 9.0 (6.8) 702, 0.8
Baseline MADRS, mean 
(SD)
33.7 (9.1) 33.4 (8.6) 34.4 (10.2) 0.5(93), 0.6
MADRS post-ECT, median 
(IQR)
6.0 (9.0) 4.0 (4.5) 18.5 (14.8) <0.1, <0.01
ECT sessions, median (IQR) 11.0 (6.0) 10.0 (4.0) 14.0 (5.3) 561, <0.01
Smoking, No. (%) 28 (35.4) 21 (38.9) 7 (28) 0.9(1), 0.3
BMI, mean (SD), n=55 23.0 (3.9) 23.1 (4.0) 23.0 (3.8) 0.33(53), 0.9
SD = standard deviation, IQR = interquartile range, No. = number, MADRS = Montgom-






n = 95 n = 65 n = 30
Psychotropic medication use
Antidepressant use, No. 
(%)
13 (13.7) 8 (12.3) 5 (16.7) 0.3(1), 0.5




22 (23.7) 12 (19.0) 10 (33.3) 2.3(1), 0.1
Hypertension, No. (%) 27 (29.0) 20 (31.7) 7 (23.3) 0.7(1), 0.4
Type 2 diabetes, No. (%) 8 (8.6) 5 (7.9) 3 (10) 0.1(1), 0.7
No. of chronic diseases 1 1 (2) 1 (2) 1 (1) 890, 0.6
Depression characteristic
Psychotic No. (%) 44 (46.3) 34 (52.3) 10 (33.3) 3.0(1), 0.1
Medication resistant, No. 
(%), n = 87
60 (69.0) 37 (61.7) 23 (85.2) 4.8(1), 0.03
Early onset, No. (%) 41 (43.2) 25 (38.5) 16 (53.3) 1.9(1), 0.1
Index episode, months, 
median (IQR)
6.0 (10.0) 5.0 (6.0) 8.0 (12.5) 509, <0.01
Markers, median (IQR) 2
CRP (mg/L, n=85) 1.4 (3.3) 2.3 (3.9) 1.0 (1.8) 505, 0.01
IL-6 (pg/ml) 2.8 (4) 3.0 (4.6) 2.4 (2.8) 829, 0.2
IL-10 (pg/ml) 0.9 (0.6) 0.9 (0.6) 0.9 (0.7) 882, 0.5
TNF-α (pg/ml) 4.3 (2.2) 4.2 (2.3) 4.4 (2.2) 960, 0.99
1 Chronic disease is defined as the total number of chronic diseases, including cara, 
CVD, hypertension, type 2 diabetes mellitus, arthroses/rheumatoid disorders
2 Marker values before log transformation
IQR = interquartile range, No. = number, CVD= cardiovascular disease, HT = hyper-
tension, DM = diabetes mellitus, CRP = C-reactive protein, IL-6 = interleukin-6, IL-10 = 
interleukin-10, TNF-α = tumour necrosis factor–α 
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Differences in clinical characteristics are shown in Table 1. CRP levels were significantly 
higher at baseline in remitters compared to non-remitters, see Table 1.
Low-grade inflammation and remission
Univariate logistic regression analysis showed that moderately elevated levels (3 to 
10mg/L) of CRP at baseline were associated with higher remission rates of depression 
post-ECT, OR: 3.31 (95% confidence interval [CI]: 1.10-9.97). In those with CRP of 3 or 
higher, remission was 83.9%, whereas remission was 61.1% in those with CRP levels 
lower than 3, OR: 3.62 (95% CI: 1.09-11.97). Other markers of inflammation, including 
dichotomized values of IL-6, IL-10, and TNF-α, were not significantly associated with 
remission of depression post-ECT (Table 2). Next, we examined low-grade 
inflammation and ECT outcome in multivariable regression analyses. Variance inflation 
factors were  <2.0 indicating no multicollinearity. Model 2 is adjusted for age, sex 
and medication-resistance. When all covariates were added in a model, 
moderately elevated CRP levels remained a significant predictor of remission of 
Table 2. Univariate and multivariate logistic regression analyses in depressed patients 
treated with ECT (n = 95)
Univariate, Model 1 Multivariate, Model 2 3
OR (95% CI) OR (95% CI)
CRP, continuous 1 2.57 (1.19-5.57) 3.16 (1.30-7.70)
Low CRP (≤ 3 mg/L) vs. 
moderately elevated CRP 
(3 to 10 mg/L) 1
3.31 (1.10-9.97) 3.62 (1.09-11.97)
IL-6 1.35 (0.81-2.23) 1.95 (0.93-4.10)
IL-10 1.47 (0.58-3.73) 1.87 (0.54-6.45)
TNF-α 2 1.20 (0.38-3.83) 1.40 (0.32-6.07)
Inflammation Composite 1.23 (0.80-1.90) 1.71 (0.81-3.62)
1 Number of patients with complete CRP is 85
2 Number of patients with complete TNF-α is 94 
3 Model 2 adjusted for medication resistance, age, and gender after backward step-
wise regression
CRP = C-reactive protein, IL-6 = interleukin-6, IL-10 = interleukin-10, TNF-α = tumour 
necrosis factor–α, inflammation composite = IL-6 and TNF-α, OR = odds ratio, CI = 
confidence interval
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depression. Post hoc analysis for the effect of CRP on remission were done, adjusting 
for BMI, since it is known that BMI has a substantial impact on both inflammation 
and depression. This was done despite the fact that there was no difference in BMI 
between patients with low or moderately elevated levels of CRP. Findings from our 
post hoc regression analyses did not alter the effect of moderately elevated CRP 
levels on remission (data available in supplemental material). Additionally, in post 
hoc analyses, no significant associations were found between baseline levels of 
inflammatory markers and use of psychotropic medication (data available in 
supplemental material). Cohen’s effect size value for CRP suggested a moderate 
impact of CRP on remission (d=0.42). The inflammation composite of IL-6 and TNF-α 
in a z-score, was not a predictor of ECT outcome, OR: 1.71 (95% CI:0.81-3.61).
Figure 1. Contribution of low and elevated CRP levels to the speed of decline in MADRS 
points, per ECT administration in depressed patients
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Inflammation and speed of decline of depressive symptoms
Using linear regression we examined the association between inflammatory markers 
and the speed of decline (defined as reduction of MADRS score relative to the number 
of ECT administrations) adjusted for all covariates using backwards stepwise 
regression. Baseline MADRS contributed significantly to the model fit. The analysis 
showed that with each natural logarithm unit increase of CRP there was a decline 
of 0.73 MADRS points per ECT administration (ß 0.73 (95% CI: 0.14-1.33) adjusted 
for age, sex, and baseline MADRS, with an R2 of 0.2. This result remained similar when 
we compared those with moderately elevated CRP levels (3 to 10 mg/L) to those with 
lower CRP levels, that is, there was an estimated decline of 3.2 MADRS points per 
administration in those with moderately elevated CRP levels vs. 2.3 points per 
administration in those with lower CRP (ß 0.97 (95% CI: 0.12-1.82), see Figure 1. We 
found no effect of other inflammatory markers on speed of decline of depressive 
symptoms,data not shown. Table 3 presents both unadjusted and adjusted results 
from the Cox regression model. The hazard ratio (HR) for remission per unit 
Table 3. Univariate and multivariate Cox proportional hazard analyses in depressed 
patients treated with ECT (n = 95)
Univariate, Model 1 Multivariate, Model 2 3
HR (95% CI) HR (95% CI)   
CRP, continuous 1 1.39 (0.97 to 1.99) 1.43 (0.99 to 2.07)
Low CRP (≤ 3 mg/L) vs. 
moderately elevated CRP 
(3 to 10 mg/L) 1
1.53 (0.91 to 2.55) 1.64 (0.96 to 2.80)
IL-6 1.08 (0.82 to 1.42) 1.11 (0.83 to 1.48)
IL-10 1.24 (0.75 to 2.04) 1.25 (0.76 to 2.07)
TNF-α 2 1.13 (0.61 to 2.12) 1.14 (0.61 to 2.13)
Inflammation Composite 1.08 (0.93 to 1.24) 1.07 (0.93 to 1.23)
1 Number of patients with complete CRP is 85
2 Number of patients with complete TNF-α is 94
3 Model 2 adjusted for age and gender after backward stepwise regression
CRP = C-reactive protein, IL-6 = interleukin-6, IL-10 = interleukin-10, TNF-α = tumour 
necrosis factor–α, inflammation composite = IL-6 and TNF-α, HR = hazard ratio, CI = 
confidence interval
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increase of CRP was 1.4 (95% CI, 0.99-2.07). All other inflammatory markers were 
not associated with speed of remission, Table 3. In Cox regression analyses, none of 
the covariates was associated with depressive symptoms. 
DISCUSSION
Our finding that moderately elevated CRP levels (3 to 10 mg/L) at baseline are associated 
with increased remission rate, improved time to remission and increased speed of 
decline of depressive symptoms in depressed patients treated with ECT was contrary to 
our primary hypothesis, i.e. moderately elevated CRP levels would contribute to poor 
treatment response. Our hypothesis was based on meta-analyses on the role of 
inflammatory markers in patients treated with antidepressant medication and on 
findings from observational studies.13,15,17 Additionally, no consistent associations were 
found between other markers of low-grade inflammation, i.e. inflammatory cytokines, 
including IL-6, IL-10, and TNF-α, and ECT response. 
Inflammation and depression
Our study shows that depressed patients with moderately elevated CRP levels, treated 
with ECT had superior outcome with higher remission rates and a greater reduction 
of depressive symptoms compared to those with low CRP levels. Our findings are 
strengthened by a preliminary study in which elevated CRP levels at baseline were associated 
with a lower end-of-treatment MADRS score, although the effect was only observed in 
women (n=15/29), not in men.30 Additionally, there was no association between CRP and 
remission, the hallmark of effective treatment of depression, likely because the remission 
rate of this study was relatively low (34%; n=10/29). In addition to CRP, Kruse et al. also 
observed an association with IL-6 and a post-ECT decrease in depressive symptoms. 
Although we found a similar contribution of CRP, we did not find an association of any 
outcome measure, including remission or speed of decline of depressive symptoms as 
a result of ECT, with baseline levels of IL-6 and other cytokines (TNF-α and IL-10). This 
difference between cytokines and CRP may be due to different kinetics for CRP and 
cytokine levels.41–43 CRP levels remain elevated over a prolonged period, when there 
is chronic stress, whereas subsequent decline to baseline for cytokines is much faster.41–43 
Since the majority of our patients were depressed for several months, before the start 
of ECT, this could explain why we did not find an association between cytokines but did 
find an association with CRP.41–43
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Possible explanations
Several hypotheses can explain the findings from our study such as (i) patients eligible 
for ECT have different characteristics compared to depressed patients in studies on 
antidepressant medication and (ii) ECT has a different working mechanism. In our view 
the latter explanation, i.e. ECT has a different working mechanism compared to anti- 
depressants, is the most plausible in explaining the effects of CRP on remission in our 
study. This view is based on the finding that non-response to antidepressants is associated 
with overall activation of the inflammatory system13,15,17,18,44, and the finding from a 
randomized controlled trial that treatment with anti-inflammatory drugs in patients 
with elevated CRP contributed to higher treatment response.45 Although a single ECT 
administration results in an immediate and transient increase of cytokine levels as 
result of an acute immune response25,28,46, multiple ECT administrations eventually 
result in normalization and long-term down-regulation of cytokine levels.24,47–49 In other 
words, ECT has an overall anti-inflammatory effect after a full ECT course, contributing 
to remission. This idea that anti-inflammatory aspects of ECT are relevant is further 
strengthened by three meta-analysis50–52 that demonstrated that anti-inflammatory 
treatments have a beneficial effect on depressive symptoms in patients with 
depressive symptoms. In addition, Vinberg et al. have found promising effects of 
anti-inflammatory treatment with erythropoietin in those patients with high levels of CRP.53 
Van Buel et al. proposed a direct role of ECT on inflammation through reinforcement of 
neurotrophin expression, that in turn, can induce neurogenesis and have antidepressant 
effects, as was observed in animal studies.28 Microglia, and innate immunity in general, 
are indispensable for central nervous system (CNS) plasticity and expression of 
neuroprotective neurotrophins, including Brain Derived Neurotrophic Factor. Van 
Buel et al. propose that chronic inflammation, which is common in patients with 
antidepressant-resistant depression and somatic comorbidity18, can bring microglia, 
the immune regulatory cells in the brain, into a state of prolonged suppression. Activation 
of the peripheral innate immune system could stimulate the microglia to resume their 
repair and antidepressant capacities in the CNS. Likewise, ECT may initiate microglia 
to produce neurotrophic factors, followed by an overall anti-inflammatory effect, which 
both may contribute to the increased remission rates observed in our study. The remission 
of depression ranges between 48% and 65% in those who fail to respond to antidepressant 
medication.23-26 It could imply that ECT could be beneficial in those patients with low grade 
inflammation who fail to respond to antidepressant medication.28
As mentioned earlier, another explanation could be that patients eligible for ECT 
have different characteristics than those in studies on antidepressant treatment. It has 
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previously been suggested that low-grade inflammation is associated with depression 
severity and subtype of depression.54,55 However, these studies are more often 
outpatient studies, or these findings are based on population-based studies. In general, 
patients eligible for ECT often have the highest severity scores of depression. In our 
study, adjustment for depression scores at baseline was a relevant covariate, since 
adjustment for MADRS score at baseline, further strengthened the association between 
moderately elevated CRP levels and speed of decline of depressive symptoms. 
Secondly, patients eligible for ECT have a shorter index episode of depression.56 Patients 
in our population had an index episode of six months, whereas, the index episode 
is significantly longer when antidepressant medication is used, i.e. more than one 
year.57 However, adjustment for index episode in our study did not alter our results. 
We were not able, in this study, to compare the association between inflammatory 
markers and a longer index episode, as described in STAR*D57 for example. We here 
present novel findings that suggest that there is a group of clinical patients with 
moderately elevated CRP levels, in whom antidepressant medication has no effect, 
who do remit when treated with ECT. Additional research is needed to confirm these 
possible mechanisms.
Strengths and weaknesses
The current study has several strengths. First, due to its sample size we were able to 
show that moderately elevated CRP levels are not only associated with a reduction in 
depressive symptoms30, we also showed that moderately elevated CRP levels were 
clinically relevant since they contributed to a significantly higher remission rate. 
Second the diagnosis of major depressive disorder with or without psychotic symptoms, 
according to the DSM-IV, was made by a psychiatrist and validated with the MINI 
International Neuropsychiatric Interview (MINI).33 Third, one could argue that the 
validity of our findings is underscored by the coherence and consistency in our finding 
when using logistic, Cox and linear regression. All statistical tests were planned and 
hypothesis driven, therefore no adjustment for multiple testing were made. 
Additionally, our study is one of the few studies to determine the effect of CRP in 
a group of patients with the highest depression scores and a relatively short index 
episode of depression before ECT started. 
In contrast, a limitation is that the sample exists of clinical, older (>55 years) patients, 
making these results not applicable to outpatients and to younger populations. 
Therefore, findings have to be replicated in severely depressed, younger outpatients 
with a relatively short index episode. It is important to note that our inflammatory 
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markers were measured on a single time point. This is a possible weakness of our 
study since it is unknown whether a single time point measure is sufficient to 
determine outcome of treatment, when inflammatory cytokines are used. On the other 
hand, there is ample evidence that a single time point measurement of CRP is a strong 
predictor for outcome of many disorders.37,58–60 Moreover findings from Browning et al. 
suggest “that use of some inflammatory markers, such as CRP, with large within- 
individual variability, will underestimate the relationship between inflammation and 
disease, and thus relationships between inflammation and chronic disease may 
be stronger than previously appreciated”.61 This makes it less likely that single time 
point measures have influenced our results. Furthermore, our findings are based on 
administration of ECT twice weekly and are thus not applicable to administration 
thrice weekly, although studies show no difference in efficacy between twice or 
thrice weekly ECT.62 In addition, we cannot compare differences in index episode and 
inflammatory markers between patients using antidepressants and patients in our study 
who received ECT, since we only have data on cytokines, CRP and patients treated with 
ECT, as described earlier in the discussion. Additionally, because the effect of psychotropic 
medication on inflammatory markers is relatively unknown63 , we cannot rule out the 
possibility that the use of psychotropic medication has influenced baseline levels of CRP 
and cytokines. However, post hoc analysis showed no significant associations between 
the two making it less likely to have influenced our findings. Also, the lack of information 
on concurrent use of anti-inflammatory medication limits our findings. To further explore 
whether ECT may have anti-inflammatory properties, future studies should include 
measurements of inflammatory markers post-ECT. Finally, we were able to adjust for 
a large number of putative confounders. Nonetheless, this is an observational study 
without control group, therefore, residual confounding through other lifestyle- or 
demographic factors cannot be ruled out. 
Implications
ECT seems to be more effective in depressed patients with moderately elevated CRP 
levels (3 to 10 mg/L), Our finding is contrary to the idea that CRP levels contribute to 
poor treatment outcome in depression and warrant replication.13,15,17 One could argue 
that ECT should be the first choice in those patients with moderately elevated CRP levels 
and severe depression. Proof for the effectiveness of such a personalized health strategy 
can only come from randomized clinical trials, comparing ECT and antidepressant 
medication, in those with severe depression and moderately elevated CRP levels.
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Supplemental Table 1. Univariate and multivariate logistic regression analyses in 
depressed patients treated with ECT
Multivariate 
Model 21 Model 32
OR (95% CI)  OR (95% CI)
CRP 3.16 (1.30 to 7.70) 8.85 (1.54 to 51.01)3
IL-6 1.95 (0.93 to 4.10) 2.67 (0.80 to 8.98)
IL-10 1.87 (0.54 to 6.45) 1.17 (0.22 to 6.13)
TNF-α 1.40 (0.32-6.07) 4.50 (0.52-38.95)3
Inflammation composite 1.71 (0.81-3.62) 4.10 (1.08-15.56)
1 Model 2 is adjusted for medication-resistant, age and gender after backwards step-
wise regression
2 Model 3 additionally adjusted for body mass index (CRP: n=44, IL-6, IL-10, and   
TNF-α: n=51)
3 Unstable regression estimate
CRP = C-reactive protein, IL-6 = interleukin-6, IL-10 = interleukin-10, TNF-α = tumour 
necrosis factor-α, Inflammation composite = IL-6 and TNF-α, OR = odds ratio, CI = 
confidence interval
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Supplemental Table 2. Correlation matrix between baseline levels of inflammatory 
markers and use of psychotropic medication during ECT
Spearman’s test for correlations




0.01 -0.11 -0.05 -0.05
CRP = C-reactive protein, IL-6 = interleukin-6, IL-10 = interleukin-10, TNF-α = tumour 
necrosis factor- α
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THE PATTERN OF INFLAMMATORY MARKERS 
DURING ELECTROCONVULSIVE THERAPY 




An association is found between changes in cytokine levels and antidepressant treatment 
outcome. Also, a proinflammatory profile is associated with a favourable electro- 
convulsive therapy (ECT) outcome. This paper investigates the pattern of inflammatory 
markers during a course of ECT in older depressed patients and whether this pattern is 
associated with ECT outcome. We hypothesized that ECT has an anti-inflammatory effect.
Methods
The pattern of CRP, IL-6, IL-10, and TNF-α during a course of ECT was examined using 
longitudinal mixed model analyses. Serum samples were collected in 99 older depressed 
patients (mean age: 72.8 ± 8.3 years, MADRS score 33.8 ± 9.0). 
Results
After Bonferroni correction, there were no statistically significant alterations in levels 
of inflammatory markers during and after ECT. Effect sizes (Cohen’s d) were -0.29 for 
CRP, -0.13 for IL-6, -0.06 for IL-10 and -0.07 for TNF-α. Changes in CRP or cytokine levels 
did not differ between remitters and non-remitters. Median baseline levels of CRP were 
significantly higher in remitters.
Conclusions
A small to medium effect size towards decreased CRP and IL-6 levels was observed. 
An anti-inflammatory effect of ECT could not be confirmed. However, the findings may 
suggest that patients with an inflammatory profile benefit more from ECT than other 
patients. Further studies are needed to confirm these findings.
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INTRODUCTION
The relation between depression and inflammation has become clearer over the past 
years as findings of higher levels of cytokines and C-reactive protein (CRP) in depressed 
patients are extensively described.1–4 For example; more than half (50 to 57%) of all 
depressed patients (both population-based and in- and outpatient samples) have 
moderately elevated levels of CRP (>1 mg/L), and about a quarter (16% to 27%) of 
patients experience low-grade inflammation (CRP >3 mg/L).5 The overall pattern of 
inflammatory markers before and after pharmacological treatment for depression 
has been examined: three meta-analyses suggested a decrease in interleukin-6 (IL-6) 
of which two also found a decrease in interleukin-10 (IL-10) and tumour necrosis 
factor-alpha (TNF-α) after antidepressant medication.6–8 Comparing these findings 
between responders and non-responders showed a decrease in TNF-α in responders 
only suggesting an association between nonresponse and persistent levels of TNF-α 
after antidepressant medication. A follow up of this meta-analysis9 again found a 
decrease in TNF-α in responders and no differences in CRP, IL-6 and IL-10 between 
responders and non-responders.6,9
Along with antidepressant medication, electroconvulsive therapy (ECT) is a very effective 
treatment for depression.10,11 It is hypothesized that a single ECT session increases 
inflammatory markers. Two reviews suggest that this initial immunological response 
is followed by a reduction in inflammatory markers at the end of the course 
of treatment suggesting an anti-inflammatory effect of ECT.12–14 However, as 
depression is often accompanied by inflammation1–4 it is also possible that the 
decrease in depressive symptoms causes the decrease in inflammatory markers 
and not necessarily a direct result of ECT. Other studies found no change in 
inflammatory markersafter ECT; an overview of studies examining inflammatory 
markers before and after ECT is given in Table 1.15–24 Remarkably, one study19 
observed unchanged levels of IL-6 towards the end of ECT in the total group, 
however, a decrease in responders, suggesting that a decrease in inflammation 
is accompanied by a decrease in depressive symptoms. In addition, in a previous 
study, we found that patients with elevated levels of CRP have a favourable 
treatment outcome.25 In light of the previous findings, this paper aims to 
investigate the pattern of inflammatory markers (CRP, IL-6, IL-10, TNF-α) during 
a course of ECT in older depressed patients and to investigate whether this pattern 
is associated with ECT outcome. If responders and non-responders show distinctive 
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working mechanism of ECT and 2) help identify which patients can benefit from 
ECT. We hypothesize that ECT has an anti-inflammatory effect as is found in studies 
examining antidepressant medication. 
METHODS
Participants
Data were collected from the Mood Disorders in Elderly treated with Electroconvul-
sive Therapy (MODECT) study.26 In this prospective cohort study, 110 older patients 
were recruited from the inpatient population of two psychiatric hospitals: GGZ inGeest, 
Amsterdam, the Netherlands and the University Psychiatric Center KU Leuven, Belgium. 
The ethical committees approved all procedures involving patients of both hospitals. 
Written informed consent was obtained from all patients. Inclusion criteria consisted 
of older age (> 55 years), referral for ECT and the presence of a DSM-IV27 unipolar 
depressive disorder. Exclusion criteria included bipolar disorder, a comorbid psychiatric 
disorder (for example schizoaffective disorder) or a neurological illness such as dementia, 
Parkinson’s disease and stroke. Persons with missing serum samples were excluded 
from analysis (n=11). Age, sex, and depression severity were not associated with 
attrition.
Inflammatory markers
Serum samples of CRP, IL-6, IL-10, and TNF-α were available on three time points: 
one week before the start of ECT (T0), the third week during ECT (T1), and one 
week after finishing a course of ECT (T2). Median duration of a course was 11.0 
(IQR = 7.0) sessions. Samples were collected between 07h30 and 09h30 and stored 
at -85 °C. Analyses of the inflammatory markers were performed as described before.25 
In short, immunoassays were performed at the Department of Clinical Chemistry 
of the University Medical Center, VUmc, in Amsterdam, the Netherlands. The high 
sensitive CRP kit (CRPHA) of Cobas was used to determine levels of CRP at the 
Endocrinology laboratory. Cytokine levels were determined using the Simoa 
Human Cytokine 3-Plex A assay kit at the Neurochemistry laboratory. All samples 
of one patient were assayed in one run and quality control samples were included. 
The intra- and inter-assay reproducibility coefficients amount 4.3% and 5.9% for 
IL-6, 3,9% and 5.3% for IL-10 and 4,2% and 5.3% for TNF-α, respectively. 
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Measures
Depression severity was measured before, weekly during and after a course of ECT using 
the Montgomery-Åsberg Depression Rating Scale (MADRS).28 The scale has a range 
between zero and 60 points. Remission was defined as a MADRS score below 10 at 
two consecutive ratings.29 Response was defined as a decrease in MADRS score of at 
least 50%.30 Clinical and socio-demographic characteristics of patients were collected in 
a semi-structured interview as well as information on comorbid diseases such as 
cardiovascular diseases, rheumatoid disorders and diabetes mellitus. 
ECT procedure
ECT was administered twice a week with the Thymatron System IV (maximum energy 
of 200%). According to Dutch guidelines31, a dose titration protocol was used to 
determine stimulus intensity: initial seizure threshold x6 for right unilateral ECT and 
x2.5 for bilateral ECT. When the motor seizure duration was shorter than 20 seconds 
or the EEG seizure duration was less than 25 seconds, the dose was raised. 31 Patients 
started with unilateral ECT and were switched to bilateral ECT if clinical conditions 
worsened or if there was no clinical response after six ECT sessions. Two-third of 
patients received solely unilateral ECT. ECT was continued until patients achieved 
remission, or until no further clinical improvement was seen after a minimum of six 
unilateral and six bilateral sessions. Psychotropic medication was tapered off at 
least one week before ECT or was kept stable when discontinuing medication was 
considered impossible. In total, 8 and 14 patients continued to use antipsychotics 
and/or antidepressants, respectively.
Statistical analyses
Baseline characteristics are summarized in means with standard deviation (SD), median 
with interquartile range (IQR) and as percentages. Normality was examined using 
visual exploration of the data. To avoid bias as a result of inflammatory diseases 
and acute infection we excluded outliers according to Q1 – 3*IQR and Q3 + 3*IQR. 
Whenever an outlier was detected for CRP the entire sample on that time point 
was excluded. Four patients had outliers on two time points, 12 patients had outliers 
on one time point. A linear mixed model was performed to detect how inflammatory 
markers varied during ECT and how the pattern of inflammatory markers varied 
between subgroups of patients. Mixed model analysis was chosen as it allows for 
correlation between repeated measurements, it allows for multivariable analysis, 
and it allows for missing variables in the dependent variables, that is, inflammatory 
markers on three time points. The subgroups of patients were defined as remission 
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n = 99 1 n = 66 n = 32 p
Sociodemographics
Age, years, mean (SD) 72.8 (8.3) 73.3 (8.2) 72.2 (8.5) -0.6(96), 0.5
Women, No. (%) 66 (66.7) 42 (63.6) 23 (71.9) 0.7(1), 0.4
Inclusion site, Amsterdam, 
No. (%)
56 (56.6) 33 (50.0) 22 (68.8) 3.1(1), 0.1
Depression characteristics
Baseline MADRS, mean 
(SD)
33.8 (9.0) 33.4 (8.5) 34.3 (10.1) 0.5(95), 0.7
MADRS after ECT, mean 
(SD)




47 (50.5) 31 (48,4) 17 (53.1) 0.2(1), 0.7
Inflammatory disease 2, 
No. (%)
35 (36.1) 23 (34.8) 12 (37.5) 0.1(1), 0,8
BMI, mean (SD), n=67 23.5 (4.1) 23.4 (3.9) 23.4 (4.0) -0.0(64), 0.97
ECT characteristics
ECT sessions, median (IQR) 11.0 (7.0) 10.0 (4.0) 14.0 (5.8) 628, <0.01*
Switched to bilateral ECT, 
No. (%)
31 (31.3) 9 (13.6) 22 (68.8) 30.2(1), <0.01*
Use of antidepressants, 
No. (%), n=82
14 (14.1) 8 (12.1) 5 (15.6) 0.2(1), 0.6
Use of antipsychotics, No. 
(%), n=82
8 (8.1) 6 (9.1) 2 (6.3) 0.2(1), 0.6
1 Only 98 patients had values on remission. 
2 including rheumatoid disorder, diabetes mellitus, and chronic inflammatory lung 
diseases
SD = standard deviation, IQR = inter quartile range, No. = number, MADRS =  
Montgomery Åsberg depression rating scale
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and non-remission and as responders and non-responders. All analyses were 
adjusted for age and sex. Additional adjustment for baseline depression severity 
was performed in the between-group analysis as depression severity can affect 
response and remission rates. A Bonferroni correction for multiple comparisons 
was used setting the statistical significance level at alpha=0.0125. Line graphs are 
plotted from univariable analyses for simplicity reasons. Post hoc analysis was 
performed to compare baseline median levels in inflammatory markers between 
remitters and non-remitters. Effect sizes (Cohen’s d) were calculated for within-group 
changes in biomarkers and were interpreted according to Cohen’s references: 0.2 small 
effect, 0.5 medium effect, and 0.8 large effect.32 Analyses were performed using SPSS 
version 23 and STATA version 14.  
RESULTS
Remission and response were reached in 66.7% (66/99) and 77.8% (77/99) of patients 
respectively (Table 2). In total, 90 serum samples were available before the start of ECT 
(T0), 83 at the third week of ECT (T1), and 86 one week after finishing an  ECT course 
(T2). Attrition was differential concerning the number of chronic diseases in T0, that is, a 
higher number of chronic diseases was found in the excluded samples. Attrition was not 
associated with age, sex and depression severity.
Changes in inflammatory markers
CRP levels decreased after a course of ECT (β = -0.91; 95%CI=(-1.75,-0.08); Cohen’s 
d = -0.29, p-value = 0.03, Figure 1) compared with baseline levels. Initially, CRP levels 
increased during ECT (β = 1.06; 95%CI=(0.22,1.91), p-value=0.01) compared with 
baseline levels with a medium effect size (Cohen’s d = 0.34), see Figure 1. Both 
comparisons were not considered significantly different after Bonferroni correction. 
There were no statistically significant alterations in levels of IL-6, IL-10, and TNF-α during 
and after ECT compared to cytokines levels before ECT (Figure 1), and effect sizes 
were small (ranging from -0.11 to -0.13 for IL-6 and -0.04 to -0.07 for IL-10 and TNF-α). 
Results remained similar after adjustment for age and sex. Post hoc adjustment 
for baseline depression severity gave similar results.
Changes after ECT in remitters and non-remitters
Overall, no statistically significant changes in CRP and cytokine levels were found 
after a course of ECT both in remitters and non-remitters (Figure 1) and in responders 
and non-responders (data not shown); in non-remitters (n=33), small to medium effect 
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Figure 1. Predicted mean values of CRP, IL-6, IL-10 and TNF-α over the course of ECT in 
depressed older patients. T0 = before ECT, T1 = three weeks after start of ECT. T2 = one 
week after finishing ECT
Error bars represent standard error of the mean estimated with linear mixed model 
analysis. After correction for multiple comparisons, no significant differences were found over 
the course of ECT overall or between remitters and non-remitters. Effect sizes for changes in 
inflammatory markers after ECT were: Cohen’s d: CRP = -0.29, IL-6 = -0.13, IL-10 = -0.06  and 
TNF-α = -0.07. 
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sizes were found for the decrease of CRP, IL-6, IL-10 and TNF-α  after a course of ECT 
(Cohen’s d = -0.02, -0.27, -0.31 and -0.54 respectively), and in remitters (n=66), the 
effect sizes of change after a course of ECT were: Cohen’s d: CRP = 0.39, IL-6 = -0.13, 
IL-10 = -0.04  and TNF-α = 0.01. Results remained similar after adjustment for age, 
sex, and baseline depression severity. 
Changes during ECT in remitters and non-remitters
The increase in CRP during ECT was different for remitters and non-remitters but was 
not considered statistically significant after Bonferroni correction for multiple 
comparisons. Overall, no statistically significant differences were found in levels of 
IL-6, IL-10 and TNF-α between remitters and non-remitters (Figure 1) and between 
responders and non-responders (data not shown). Results remained similar after 
adjustment for age, sex, and baseline depression severity.
In a post hoc analysis, CRP levels at baseline were compared between remitters and 
non-remitters showing higher levels in remitters (Remitters: median 2.8 mg/L, Non- 
remitters: 1.0 mg/L, Mann-Whitney U=534, p <0.01). The baseline levels of IL-6, IL-10 
and TNF-α did not differ between groups. 
DISCUSSION
This study aimed to investigate the pattern of inflammatory markers during a 
course of ECT in older depressed patients to gain insight in the working mechanism 
of ECT and to provide information on which patients could benefit from ECT. The 
results show no statistically significant alterations in serum cytokine and CRP levels 
after ECT, after a Bonferroni correction was made, although both for CRP and IL-6 a 
small to medium effect size towards a decrease at the end of treatment was seen. 
This pattern of inflammatory markers is similar in remitters and non-remitters 
and responders and non-responders. Patients who remitted had higher levels of 
baseline CRP. These findings strengthen the possibility that especially patients with 
an inflammatory profile benefit from treatment such as ECT.
Findings from comparable studies on changes in inflammatory markers after ECT 
are summarized in Table 1. Although the sample sizes are small, overall, most studies 
are consistent with our findings, that is, unchanged levels of IL-10 and TNF-α after 
a course of ECT. Remarkably, in antidepressant medication studies, levels of TNF-α in 
particular decrease after treatment8,9, suggesting a distinct working mechanism for 
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antidepressant medication as compared to ECT. In our study, a small to medium 
effect size was found for a decrease in levels of CRP and IL-6 after ECT compared 
to pre-ECT levels (the decrease in CRP lost its statistical significance after 
Bonferroni correction). Contrary to our findings, two studies found no change 
in CRP levels after ECT.18,23 For IL-6, a decrease towards the end of ECT was found in 
three studies compared to five studies that found no change (Table 1). We would 
expect to find similarities in the pattern of CRP and IL-6 as they are interdependent: 
CRP can induce IL-6 production while IL-6 can induce secretion of CRP.33 With the 
current findings, it remains unclear whether ECT has an anti-inflammatory effect 
even though some studies point in that direction. 
Apart from examining the anti-inflammatory effect of ECT, we performed subgroup 
analyses to examine whether patients with a favourable treatment outcome 
have different CRP or cytokine patterns during ECT. No statistically significant 
differences were found in the overall pattern of CRP, IL-6, IL-10 and TNF-α between 
remitters, non-remitters, responders, and non-responders. To our knowledge, our 
study is the third study examining the pattern of inflammatory markers stratified 
for treatment outcome. The two previous studies found a decrease in IL-6 towards 
the final ECT session in remitters only19, and a trend towards decreased IL-6 levels 
in responders only.22 In our study, a medium effect size for the decrease in IL-6 in 
non-remitters was found, however, we believe it was distended by the small 
number of non-remitters (22/99). Besides, a small effect size was found for the 
decrease in IL-6 in remitters and the total sample. Our study differs from most 
previous studies as we used a linear mixed model rather than a paired difference 
test (Wilcoxon, Kruskal-Wallis or paired T-test), allowing for confounder adjustment 
and missing values, leading to more reliable results. The present findings indicate 
that even if ECT would have anti-inflammatory properties, it is independent from 
therapeutic effect. In a previous study, we found that patients with higher levels of 
CRP before ECT are more likely to remit from depression after ECT.23,25 We were 
interested whether alterations in CRP levels during ECT corresponded between 
remitters and non-remitters. The present findings suggest that the CRP and cytokine 
patterns were independent from ECT outcome. Although not the primary focus 
of our study, we found that levels of CRP were higher at baseline in remitters 
compared to non-remitters. Similar findings are described for IL-6 levels and a 
trend for CRP levels in a comparable study.23 This may suggest that patients with 
higher levels of inflammation are most likely to benefit from ECT. In comparison, 
recent meta-analyses have found that antidepressant medication response is 
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independent from baseline levels of inflammation.9 If these findings are confirmed, 
personalized treatment plans could include some patients being treated with medication 
and others - patients with an inflammatory profile or higher baseline CRP - with ECT. 
The concept that anti-inflammatory properties are important in the treatment of 
depression is not new.34,35 Several meta-analyses examined whether changes in 
cytokine levels were associated with antidepressant treatment outcome.7–9,36 The 
high amount of nonresponse with traditional antidepressants have stimulated the 
search for other treatment options for depression. Studies have shown that 
monotherapy or add-on therapy with anti-inflammatory agents such as non- 
steroidal anti-inflammatory drugs (NSAID), cytokine inhibitors, or statins, can 
reduce depressive symptoms.37–40 This effect is also seen in patients with chronic 
inflammatory diseases where depressive symptoms were measured as a secondary 
outcome measure.41 Antidepressant treatments with anti-inflammatory properties 
may be especially effective in patients who experience higher baseline inflammation, 
for example, patients with inflammatory diseases. This hypothesis is strengthened by 
the above-mentioned finding that higher baseline levels of CRP are associated with 
higher chances of remission after ECT.23,25 
Strengths and limitations
A strength of this study is the relatively large sample size compared to similar studies. 
As a result of this, we were able to compare patterns of inflammatory markers in 
subgroups of patients. Another strength is the use of linear mixed model analysis 
for longitudinal data, allowing us to control for confounding variables. The use of an 
older patient group hampers comparison of our findings with other studies. 
However, inflammation is more common in older patients42–44, therefore it is important 
to look at the relationship between inflammation and ECT in older people. Unknown 
is whether the differences in inflammation levels between older patients may be 
smaller than in adults possibly causing an underestimation of changes in cytokine 
pattern during ECT. Next, some patients used antipsychotic and antidepressant 
medication, both have been found to alter inflammatory markers.45 A consideration 
was whether to correct for multiple testing. This study included analyses of four 
biomarkers in remitters, non-remitters, responders and non-responders, thus, 
we corrected for multiple testing to reduce the risk of a type I-error. However, 
this decision automatically increases the risk of rejecting a true H1 hypothesis.46 The 
use of effect sizes assists in interpreting our findings. A control group would facilitate 
comparison of the pattern of inflammatory markers within depressed patients not 
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receiving ECT. Finally, the use of stimulated cytokines, that is, measurement of 
cytokines in blood samples after adding lipopolysaccharide, would facilitate in 
measuring the cytokine production capacity and could be considered in future studies. 
In conclusion, in this relatively large sample of older depressed patients receiving ECT, 
a small to medium effect size towards decreased CRP and IL-6 levels after a course of 
ECT was found. Patients who remit after ECT have similar patterns of inflammatory 
markers during ECT as patients who do not remit, albeit remitters had higher levels 
of baseline CRP. With the present findings, an anti-inflammatory effect of ECT could 
not be confirmed. However, the findings suggest that patients with an inflammatory 
profile benefit more from ECT than other patients. Further research, for example, 
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THE COURSE OF APATHY IN LATE-LIFE 





Apathy, a lack of motivation, is frequently seen in older individuals, with and without 
depression, with substantial impact on quality of life. This prospective cohort study of 
patients with severe late-life depression treated with electroconvulsive therapy (ECT) 
aims to study the course of apathy and the predictive value of vascular burden and in 
particular white matter hyperintensities on apathy course. 
Methods
Information on apathy (defined by a score of >13 on the Apathy Scale), depression severity, 
vascular burden, and other putative confounders was collected in at two psychiatric 
hospitals on patients with late-life depression (aged 55 to 87 years, N=73). MRI data 
on white matter hyperintensities were available in 52 patients. Possible risk factors for 
apathy post-ECT were determined using regression analyses. 
Results
After treatment with ECT, 52.0% (26/50) of the depression remitters still suffered from 
clinically relevant apathy symptoms. In the entire cohort, more patients remained 
apathetic (58.9%) than depressed (31.5%). Presence of apathy post-ECT was not 
associated with higher age, use of benzodiazepines, or severity of apathy and 
depression at baseline. Less response in depressive symptomatology after ECT 
predicted post-treatment apathy. The presence of vascular disease, diabetes mellitus 
and smoking, and white matter hyperintensities in the brain was not associated with 
post-treatment apathy. 
Conclusions
Apathy may perpetuate in individual patients, despite remission of depressive symptoms. 
In this cohort of patients with late-life depression, post-ECT apathy is not associated 
with white matter hyperintensities. 
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INTRODUCTION
Apathy is defined as “a lack of motivation that is not attributable to a diminished level 
of consciousness, cognitive impairment or emotional distress”.1 Apathy is frequently 
present in older individuals (>65) and patients with neurological and psychiatric 
disorders such as Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, 
stroke and major depression. 1–4 The impact of apathy on quality of life is substantial.5,6 
To date, it remains unclear whether apathy is an independent behavioral syndrome; 
albeit studies increasingly recognize it as such.2,5,7–12 In the context of depressive illness 
apathy is a complex issue. Since symptoms partly overlap, it remains an endeavor to 
disentangle to what extent lack of motivation is a depressive symptom or part of an 
independent syndrome. Insight in this complex matter may be derived from studies on 
the course of apathy in depression treatment. 
To our knowledge, two randomized clinical trials13,14 and one prospective cohort study5 
have investigated the course of apathy in older patients with depression. The first two 
studies investigated the course of apathy during treatment with selective serotonin 
reuptake inhibitors (SSRI), both demonstrating an improvement in depression severity 
and a partial response of apathy symptoms, independent from each other.14 The 
longitudinal, naturalistic study of Groeneweg-Koolhoven et al.5 demonstrated 80% 
persistence of apathy and 41% persistence of depression in a group of 199 older persons 
with depression during 2-year follow-up. 
It has been suggested that apathy is strongly linked with white matter hyperintensities 
(WMH)9,15–21 and, therefore, post-depression-treatment apathy may be (partly) due to 
vascular brain damage. To date, studies that have examined the impact of WMH on 
post-depression-treatment apathy are scant. Yuen et al.14 investigated the impact of 
neuroanatomical correlates on the response of apathy to SSRI treatment in depressed 
non-demented, older persons. They found that structural brain changes may interfere 
with prefrontal cortical recruitment of limbic activity, which is essential for motivated 
behavior. This could, at least partly, explain the persistence of apathy during and after 
depression treatment.
Electroconvulsive therapy (ECT) is the most effective treatment for severe depression. 22,23 
In addition, ECT enhances the dopamine-pathways more than antidepressants.24 
Dopamine is reckoned to be at the core of motivated behavior. Research into the course 
of apathy in depressed persons during ECT and the role of vascular burden and in 
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particular WMH reflecting ischemic small vessel disease may provide further insight into 
this complex matter. The Mood Disorders and ECT study (MODECT), a prospective cohort 
study consisting of older persons referred for ECT, provides an excellent opportunity to 
study the course of apathy during ECT since information on depression severity, apathy, 
vascular disease, and WMH is available.25 Based on prior studies5 we hypothesize that a 
majority of older depressed persons will have significant symptoms of apathy, despite 
remission of depressive symptoms following ECT treatment. In addition we hypothesize 
that post-depression-treatment apathy is associated with WMH. 
METHODS
Study sample
Data in this study were derived from the MODECT, a prospective cohort study.25,26 In total, 
110 older persons (age >55 years) with a unipolar major depressive disorder according 
to the DSM-IV criteria27 referred for ECT, were recruited from two psychiatric hospitals 
(GGZinGeest, Amsterdam, the Netherlands and University Psychiatric Center, KU Leuven, 
Belgium). Exclusion criteria were a major neurological illness (including dementia and 
Parkinsons’s disease), or a DSM-IV diagnosis of bipolar- and schizoaffective disorder. 
Diagnoses were made by a psychiatrist and confirmed by the Mini-International 
Neuropsychiatric Interview.28 Persons with missing values on the Apathy Scale (AS) at 
baseline (before the start of ECT) and one week after final ECT session were excluded 
(n=37). Attrition was differential with respect to baseline psychomotor symptoms, 
which was higher for excluded subjects. Other factors (age, sex, years of education, life 
threatening symptoms as primary indication for ECT, depression severity, age of onset, 
cognitive functioning, vascular burden and in particular WMH) were not associated with 
attrition.
ECT procedures
Patients received ECT twice weekly, preferably starting with right unilateral stimuli. All 
treatments were administered using the Thymatron System IV (maximum energy 200%, 
1008 mCoulombs) using a titration dosing protocol. A motor seizure duration less than 
20 seconds or a seizure duration less than 25 seconds on EEG recordings was considered 
inadequate, after which the dose was raised according to Dutch guidelines.29 If clinical 
condition worsened, i.e. increase in total MADRS scores, increased suicidality, dehydration 
or weight loss, occurrence of psychotic features or if no clinical improvement occurred 
after six ECTs, a switch to bilateral ECT was applied. ECT was continued until remission 
- defined as Montgomery Asberg Depression Rating Scale (MADRS) scores lower than 
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ten at two successive ratings – was achieved, or when no further improvement occurred 
during two weeks, despite sufficient treatments (e.g. a minimum of six unilateral and six 
bilateral sessions). Psychotropic medications, e.g. antidepressants, anti-epileptics, and 
benzodiazepines, were tapered off within two weeks before start of ECT treatment. 
Measures
Clinical assessments were conducted before start of treatment (T0) and one week after 
completion of treatment (T1). Apathy was assessed with the Apathy Scale (AS), which 
has 66% sensitivity and 100% specificity to categorize patients as apathy versus no 
apathy (validated in Parkinson disease patients).30,31 The AS consists of 14 items, each 
with a four-answer scale (0-3; not at all, slightly, some, and a lot). Post-depression- 
treatment apathy (further on mentioned as post-treatment apathy), was defined as a 
score on the AS higher than 13, higher scores indicate more severe apathy.30,32 Information 
on discriminant validity is not available. However since the AS is based on the Apathy 
Evaluation Scale, a comparable good discriminant validity is assumed.31,33 The MADRS 
was used to measure severity of depression. It consists of ten questions rated 
from 0-6 with a total score 60.34 Early age of onset was defined as an onset of depression 
before 55 years. Somatic history was assessed prior to treatment in a semi-structured 
interview and included pulmonary disorders, arthrosis, (rheumatoid) arthritis, 
malignant neoplasms, migraine, thyroid disease, Parkinson’s disease, other disease 
of the central nervous system, consequences of an accident (fractures, head injury 
or burns) and permanent disability due to surgery. Vascular disease was defined as 
a history or current treatment of hypertension, myocardial infarction (MI) and 
cerebrovascular disease. Additionally a variable vascular burden was defined as 
presence of at least one of the following conditions: vascular disease, diabetes mellitus 
(DM) or smoking. Smoking was categorized as never or ever (including current use) 
and alcohol use as less than monthly or two times a month or more. Cognitive 
functioning was assessed by the Mini-Mental State Examination (MMSE, range 0-30)35 
and was conducted weekly. Psychomotor symptoms including, agitation, retardation and 
non-interactiveness were measured using the 18-item CORE assessment of psychomotor 
symptoms, total score range from 0 to 54.36 Finally, for apathy (AS), depression severity 
(MADRS) and psychomotor symptoms, change scores were calculated by subtracting the 
total score at T1 from T0. 
Magnetic resonance imaging (MRI)
MRI data were analyzed on the presence and severity of WMH by an independent 
neuroradiologist. A validated visual rating scale established by Fazekas37 was applied in 
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order to grade the severity of deep subcortical white matter hyperintensities (subcortical 
WMH): 0 (no or single punctate white matter lesions), 1 (punctate white matter lesions), 
2 (beginning confluent lesions), 3 (large confluent lesions). In addition, periventricular 
white matter hyperintensities (periventricular WMH) were assessed on a three-point 
scale: 0 (no structural abnormalities), 1 (thin lining lesions), 2 (>5mm lesions).37 All MRI 
measures were rated on FLAIR images. In our sample of 73 patients, MRI data were 
available for 52 people (71%) which were all included in analysis. Attrition analysis 
showed that persons with missing MRI data were comparable for all dimensions to those 
with MRI data. 
 
Statistical analyses
Comparisons of the distribution of characteristics across post-treatment apathy and no 
post-treatment apathy were made using the two-tailed chi-square test for dichotomous 
variables, and the Student T-test or Mann-Whitney U-test for continuous variables. 
Assumptions of normality were made with use of skewness and kurtosis measurements. 
In addition, in a subsample of persons with remission of depression, the number of 
persons with post-treatment apathy was calculated. Pearson’s or Spearman’s test for 
correlations were used to examine correlations between change scores in MADRS, 
AS, vascular disease, alcohol use and WMH. To determine which clinical characteristics 
might predict post-treatment apathy after ECT treatment we performed multivariate 
logistic regression analyses. Odds ratio’s (OR) are presented with their 95% confidence 
intervals (CI). Demographic variables (age, sex), vascular burden (hypertension, 
myocardial infarction, diabetes mellitus, cerebrovascular disease, smoking) and MRI 
measures (subcortical WMH and periventricular WMH) were entered in the model. MRI 
measures were entered in the models separately. Additionally, multicollinearity was 
tested. The same analysis was performed using linear regression. Effect sizes were 
calculated for all vascular burden measures using Cohen’s d and were interpreted 
according to Cohen’s widely used references; 0.2 small effect, 0.5 medium effect, 0.8 




Apathy was present at baseline in 93.2% (68/73) of patients (AS>13) with a total mean AS 
score of 24.7 (SD ± 7.4). The mean population age was 71.9 years (range 55-87 years) and 
47 patients (64.4%) were women (Table 1). 50 patients out of 73 (68.5%) remitted from 
depression after ECT treatment (MADRS <10). 
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Table 1. Baseline characteristics, vascular burden and white matter hyperintensities 
in the total cohort split up for post-treatment apathy and no apathy.
Total
No 
Apathy 1 Apathy 1 T/X/U(df)
n = 73 n = 30 n = 43 p
Sociodemographic
Age, years, mean (SD) 71.9 (8.8) 69.5 (8.4) 73.5 (8.9) -1.9(71), 0.05
Women, No. (%) 64.4 63.3 65.1 0.02(1), 0.9
Level of education in years, 
median (IQR)
9 (3) 9.5 (6) 9 (1.3) 377, 0.3
Age of onset, early <55y, 
No. (%)
46.6 43.3 48.8 0.2(1), 0.6
Baseline MMSE, 
median (IQR)
26 (5.3) 26 (6) 26 (5) 427, 0.8
Highest MMSE, 
median (IQR)
29 (3) 28.5 (3.3) 29 (4) 631, 0.9
MMSE after ECT, 
median (IQR)
27 (4) 27 (4) 28 (4.5) 533, 0.8
Baseline MADRS, mean (SD) 32.7 (8.6) 33.3 (7.8) 32.2 (9.2) 0.5(66), 0.6
Δ MADRS; mean (SD) 23.2 (11.4) 28.4 (8.3) 19.7 (12) 3.3(66), <0.01
Baseline AS, mean (SD) 24.7 (7.4) 23.5 (8.4) 25.6 (6.6) -1.1(52), 0.3
Δ AS, mean (SD) 8.3 (8.7) 13.7 (8.3) 4.4 (6.7) 5.3(71), <0.01
Baseline CORE, mean (SD) 13.7 (7.9) 14.7 (8.4) 13.1 (7.7) 0.8(64), 0.4
Δ CORE, mean (SD) 9.5 (8.6) 12.7 (8.7) 7.4 (8.1) 2.5(63), 0.02
Benzodiazepines use, 
No. (%)
46.6 50 44.2 0.2(1), 0.6
Alcohol use, No. (%) 20.6 25.9 17.1 0.8(1), 0.4
1 Apathy defined as AS 14-42, No apathy defined as AS<14
SD = Standard Deviation, IQR = Inter quartile range, MMSE = Mini-mental State Ex-
amination, Highest MMSE = Highest score in the course of treatment, CORE = CORE 
assessment of psychomotor symptoms, MADRS = Montgomery Asberg Depression 
Rating Scale, AS = Apathy Scale
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Apathy after ECT treatment
Post-treatment apathy was seen in 43 patients (58.9%), with a mean AS score of 21.1 
(SD ± 4.9). In these patients, the average decrease in AS was 10.6% (SD ± 16.0%) from 
baseline compared to 32.7% (SD ± 19.8%) in patients without post-treatment apathy. 
In the entire cohort more patients remained apathetic (58.9%) than depressed (31.5%). 
As shown in Table 2, 23 of 41 (56.1%) post-treatment apathy patients showed remission 
of depression. The mean baseline MADRS for all patients was 32.7 (SD ± 8.6), 
indicating severe depression in this hospitalized cohort. Mean decrease in MADRS was 
23.2 (SD ± 11.4). There were no significant differences in clinical characteristics, vascular 
disease, and the presence of WMH across post-treatment apathy and no apathy groups. 
Pearson’s test for correlation indicated a positive association between change scores 
in MADRS and the AS (0.57), change scores in MADRS and CORE (0.68) suggesting an 
overlap in measurements. Little improvement in depressive symptoms (total MADRS 
score) proved to be a significant predictor of post-treatment apathy after ECT treatment 
in univariate analyses, OR = 0.9; 95%CI = (0.87-0.98), whereas older age, OR = 1.06; 95% 
CI = (0.99-1.12), use of benzodiazepines, OR = 0.79; 95%CI = (0.31-2.02), age of onset, 
OR = 0.8; 95%CI = (0.31-2.05), high baseline apathy scores, OR = 1.04; 95%CI = 
(0.98-1.11) and high baseline MADRS scores, OR = 0.99; 95%CI = (0.93-1.04) were not. 
Since late-life depression is associated with neurodegenerative disorders, pre-clinical 
dementia should be considered as a possible cause of apathy in our sample.39 
Therefore post-hoc analyses were performed. First, the highest score of the weekly 
MMSE-measurements during the course of ECT were determined. MMSE scores <24 
Table 1. Continued
Vascular burden, No. (%)
Hypertension 31.9 31 32.6 0.02(1), 0.9
Myocardial infarction 29.2 24.1 32.6 0.58(1), 0.3
Smoking 38.1 44 34.2 0.6(1), 0.4
Diabetes Mellitus 6.9 3.4 9.3 0.9(1), 0.3
Cerebrovascular disease 1.4 0 2.3 0.68(1), 0.4
Subcortical WMH, mean 
(SD), n=52
1.2 (0.8) 1.1 (0.7) 1.3 (0.8) -0.98(50), 0.3
Periventricular WMH, mean 
(SD), n=52
1.1 (0.7) 1 (0.6) 1.2 (0.7) -1.2(50), 0.3
SD = Standard Deviation, WMH = White matter hyperintensities
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were considered as poor cognitive functioning, susceptible for putative pre- 
clinical dementia. Next, associations between poor cognitive functioning and 
apathy groups were examined. No statistical differences were found in poor 
cognitive functioning between Apathy and No apathy groups, X2(1) = 0.01, 
p = 0.61. Likewise, in univariate analysis a MMSE score of <24 did not prove to be a 
significant predictor of post-treatment apathy, OR = 0.9; 95%CI = (0.19-4.46). Finally, 
baseline MMSE and post-treatment MMSE scores did not prove to be predictors of 
post-treatment apathy, respectively OR = 1.0; 95%CI = (0.89-1.13) and OR = 0.95; 95%CI 
= (0.82-1.11). Additionally, bilateral ECT is thought to have a higher impact on cognition 
than unilateral ECT and therefore the number of patients with post-treatment apathy, 
stratified for unilateral or bilateral ECT, was examined in a post-hoc analysis. In patients 
who received unilateral ECT (n = 50), 48% of the patients with apathy at baseline were 
also apathetic at follow-up. In patients who received solely bilateral ECT (n = 4) or who 
shifted toward bilateral ECT (n = 18), 77.3% of the patients with apathy at baseline 
remained apathetic. Regression analyses were additionally adjusted for ECT-technique. 
However, findings remained largely similar: Model 1 OR = 0.98; 95%CI = (0.54-1.77), 
Model 2 OR = 0.95; 95%CI = (0.49-1.86), Model 3 OR = 0.87; 95%CI = (0.43-1.77) and 
Model 4 OR 0.81; 95%CI = (0.33-1.95).
Apathy and vascular burden
In multivariate analyses, we examined the association between post-treatment apathy 
and vascular burden including hypertension, MI, DM, cerebrovascular disease, smoking, 
and WMH (subcortical WMH and periventricular WMH). As shown in Table 3, all vascular 
and MRI measures were entered in separate models, adjusted for age, sex, and change 
scores in MADRS. In both model 1 and model 2 older age (OR = 1.09; 95%CI = (1.02-1.17) 
Table 2. Within group frequencies (n = 73)
Remission of No remission of 
depression depression
Post-treatment apathy, Apathy at baseline 23, 46.0% 18, 78.3%
Post-treatment apathy, No apathy at baseline 3, 6.0% 0
No post-treatment apathy, Apathy at baseline 22, 44.0% 5, 21.7%
No post-treatment Apathy, No apathy at 
baseline





and change score in MADRS (OR = 0.91; 95%CI = (0.86-0.97) were significantly associated 
with post-treatment apathy. After adjustment for subcortical WMH and periventricular 
WMH in model 3, change score in MADRS, OR = 0.94; 95%CI = (0.88-0.99), remained a 
predictor for post-treatment apathy, whereas older age, OR = 1.08; 95%CI = (0.99-1.18) 
did not. Vascular burden, OR = 0.8; 95%CI = (0.2-3.11), and smoking, OR = 0.5; 95%CI = 
(0.14-1.76), was not associated with post-treatment apathy. Model 3 shows the Fazekas 
scale, e.g. subcortical WMH and periventricular WMH, and was added separately to 
multivariate analyses, showing the absence of an association with post-treatment apathy 
(Subcortical WMH: OR = 1.07; 95%CI = (0.39-2.95) and Periventricular WMH: OR = 1.04; 
95%CI = (0.34-3.17). When entered in the model together with vascular burden (model 4) 
none of the measures was associated with post-treatment apathy (see Table 3). 
Table 3. Multivariate logistic regression analyses on post-treatment apathy.
Model 1 Model 2 Model 3 Model 4 
n = 68
OR (95% CI) 
n = 58
OR (95% CI) 
n = 50
OR (95% CI) 
n = 41
OR (95% CI) 
Demographics
Age 1.09 (1.02-1.17) 1.08 (1.00-1.16) 1.08 (0.99-1.18) 1.07 (0.97-1.18)
Sex 0.76 (0.23-2.58) 0.62 (0.15-2.55) 1.07 (0.29-3.98) 0.96 (0.19-4.98)
Psychopathology
Delta MADRS 0.91 (0.86-0.97) 0.92 (0.86-0.98) 0.94 (0.88-0.99) 0.94 (0.88-1.00)
Vascular burden
Smoking - 0.50 (0.14-1.76) - 0.6 (0.13-2.66)
Vascular 
disease




- - 1.07 (0.39-2.95) 1.01 (0.34-3.02)
Periventricular 
WMH
- - 1.04 (0.34-3.17) 0.81 (0.21-3.11)
1 MRI measures are entered in the model separately. The odds ratios presented repre-
sent the model including subcortical WMH
WMH = White matter hyperintensities, OR = odds ratio, CI = confidence interval, 
MADRS = Montgomery Åsberg Depression Rating Scale
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There was no multicollinearity among predictor variables as their variance inflation 
factors were <2.0. Outcomes of linear regression analyses, using apathy change scores, 
were similar to fore mentioned results. Effect sizes were calculated for all measures of 
interest. Cohen’s effect size value for subcortical WMH (d = 0.27) and periventricular WMH 
(d = 0.31) suggested a small to moderate impact of WMH on post-treatment apathy. 
DISCUSSION
The results of our study suggest that apathy, defined by a score of >13 on the Apathy 
Scale (AS), is seen in almost two third (58.9%) of all patients after treatment with ECT. 
In total, 31.5% of patients showed persistence of depressive symptoms (MADRS>10). 
The larger number of patients with apathy as compared to persistence of depression 
suggests that a considerable number of persons suffer from post-treatment apathy, 
despite remission of depressive symptoms. This was confirmed by the finding that half 
of the remitted depression patients (26/50, 52.0%) still reported clinically relevant apathy 
symptoms. A smaller decline in MADRS scores, however, was predictive of 
post-treatment apathy. Contrary to our hypothesis, there were no differences in 
vascular burden and in particular WMH between patients with or without post-treatment 
apathy. 
Our findings are in line with Yuen et al.14, who demonstrated a clinically significant 
decrease in apathy symptoms following treatment with escitalopram. In their sample 
of older persons with depression, 43.8% had post-treatment apathy according to the 
Apathy Evaluation Scale. Depression severity decreased to a larger extent than did 
apathetic symptoms.14 The impact of post-treatment apathy on prognosis is substantial; 
Groeneweg-Koolhoven et al.5 showed that older persons with persistent apathy at two 
year follow-up were less likely to recover from depression than those that remitted from 
apathy. As was demonstrated by our findings, a smaller decline in total MADRS score was 
associated with the presence of post-treatment apathy. In addition, changes in scores of 
MADRS and AS were correlated (Pearson: 0.57) contributing to the idea of overlapping 
symptoms in depression and apathy, and apathy as a residual symptom of depression. 
In contrast, our findings showed higher recovery rates for depression as compared to 
apathy. Furthermore, severity of apathy and depressive symptoms at baseline did not 
predict post-treatment apathy, which suggests different etiologies for apathy. Finally, the 
impact of ECT on cognitive functioning, which may clinically manifest as apathy, must be 
considered. This may particularly be seen in persons with bilateral ECT, considering the 
greater impact of bilateral ECT on cognitive functioning.40 However, as post-hoc 
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analyses showed no influence of ECT technique on the presence of post-treatment 
apathy, an overestimation of apathy by means of interference with cognitive functioning 
is less plausible.
Next, we examined to what extent vascular burden may be associated with 
post-treatment apathy. We hypothesized that post-treatment apathy would be 
associated with vascular burden including a history of MI, hypertension, DM, vascular 
disease, smoking and WMH measured using the Fazekas scale. However, vascular 
burden was not significantly associated with the course of apathy during ECT. Similar 
to our results, Lampe and Heeren41 did not find an association between apathy and 
vascular risk in a cross-sectional study on 29 depressed older persons. In contrast, other 
studies have repeatedly indicated motivational symptoms as a characteristic of white 
matter lesions, lacunar infarcts or vascular disease both in presence and absence of 
depression.3,16–18,42–44 Probably, post-treatment apathy may be a final common pathway of 
various underlying pathophysiological mechanisms, especially in this cohort of persons 
with late-life depression. Further studies are needed to further elucidate this complex 
matter.
Some limitations should be noted. Depression is associated with neurodegenerative 
disorders, therefore the possibility of apathy not being related to depression in some 
patients yet being related to pre-clinical dementia must be considered. Oudega et al.39 
presented a naturalistic follow-up study (N=39) demonstrating 65.1% of patients with 
cognitive decline and 17.9% diagnosed with dementia 7-12 years after ECT treatment. 
In post-hoc analyses, we could not demonstrate an association between poor cognitive 
functioning and apathy, possibly suggesting that poor cognitive function does not 
contribute to apathy in our cohort. However, the MMSE used in our study has its 
limitations in characterizing cognitive deficits during ECT. The use of more detailed 
cognitive testing must be considered in future research. In conclusion, post-treatment 
apathy may in some patients be a clinical warning for future cognitive decline and 
dementia. Studies with longer follow-up are warranted to gain insight in the course 
of cognitive decline in persons with post-ECT apathy. In addition, previous studies 
demonstrated that WMH, are important foci in patients suffering from apathy.14,16,45,46 
These measures were therefore included in the MODECT-study. However, other studies 
suggest other regions of interest to be associated with apathy. For example, the volume 
of acute pontine infarcts is suggested to predict post-stroke apathy while periventricular 
WMH do not.44 In general, subcortical frontal brain regions seem important in the 
association between apathy and depression.7 Apart from the applied MRI measures, 
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our analysis included global cortical atrophy47,48 and medial temporal lobe atrophy.46 
However, both did not show a significant association with apathy. Including different 
brain regions must be considered in further research. Another limitation is the use of the 
Apathy Scale, which is validated in older persons with Parkinson disease and dementia. 
Albeit frequently used in research into apathy in depressed persons, unfortunately, the 
discriminant validity in depression is not available. In further research use of the Apathy 
Evaluation Scale should be considered.31,33 In addition, four-week follow-up 
measurements were not included in the analysis because of the large amount of missing 
AS data (62%). Therefore we do not know whether the improvement of apathy 
continued after the end of treatment. In future research, including qualitative comments 
from participants on the impact of depression and apathy pre- and post-treatment 
should be considered. 
 
Conclusion
In conclusion, our results indicate that two thirds of patients with late-life depression 
show apathy after treatment with ECT, as do 52% of those who achieved remission of 
depression after ECT. As the impact of apathy on prognosis and quality of life is 
substantial5,6, it is important to acknowledge this high prevalence and consider apathy 
as an invalidating independent behavioral syndrome. Moreover, the present results 
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Despite its effectiveness, patients and practitioners are often reluctant to start 
electroconvulsive therapy (ECT) due to the risk of transient cognitive side effects, 
particularly in older patients. Inflammatory processes may be associated with the 
occurrence of these effects. We assessed whether inflammatory markers prior to ECT are 
associated with cognitive functioning in depressed patients treated with ECT.
Methods
Between 2011 and 2013, 97 older patients (mean age 73.1±8.1 years) with severe 
unipolar depression (according to the DSM-IV) referred for ECT were included. We 
used Mini-Mental State Examination (MMSE) scores to determine cognitive functioning 
prior to, weekly during, and in the first week after a course of ECT. Serum levels of 
C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10), and tumour necrosis 
factor-α (TNF-α) were assessed prior to ECT.
Results
In fully adjusted models, there was an association between TNF-α and cognitive 
functioning: β = -1.05; 95%CI=(-2.04 to -0.06), f2 = 0.06). An association was also found 
between baseline levels of IL-10, TNF-α and lower MMSE scores during ECT: IL-10: 
β = -2.03; 95%CI=(-3.16 to -0.89), TNF-α: β = -0.66; 95%CI=(-1.08 to -0.24). In addition, 
an association was found between baseline CRP and lower MMSE scores directly after 
a course of ECT: β = -0.51;95%CI=(-0.93 to -0.09), f2 = 0.10). Associations with IL-6 did not 
reach significance.
Conclusions
This study suggests that inflammatory processes are associated with lower cognitive 
functioning prior to ECT, and predispose for (further) cognitive dysfunction during and 
after a course of ECT. 
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INTRODUCTION
Electroconvulsive therapy (ECT) is one of the most effective treatments for major 
depression, especially in older patients.1 Despite its effectiveness, patients and 
practitioners are often reluctant to start ECT2, partly due to fear of memory 
impairment.3,4 Indeed, several cognitive side effects with a range of manifestations 
and impact have been described, varying from post-ictal delirium5,6 to retrograde 
amnesia.7,8 In general, studies demonstrated that cognitive side effects are transient.8–13 
Meta-analyses described declined cognitive performance in the first three days after 
finishing a course of ECT and improved cognitive performance, back to baseline or 
beyond baseline levels, in the following 12 days.8 Similarly, studies on long-term 
cognitive functioning, measured with a cognitive test battery six months after ECT, 
showed no decline in cognitive performance as compared to cognitive functioning prior 
to ECT.14,15
Nonetheless, transient cognitive side effects increase treatment burden by leading to 
worse daily functioning, higher care demands, poorer quality of life and fear for ECT, 
which may result in a barrier and non-adherence to treatment.3,4 Being able to give 
information on individual risk for cognitive side effects to patients and family members 
will help avoid premature discontinuation of ECT.16–18 Moreover, strategies for minimizing 
cognitive side effects are being developed, that is, cognitive training19, administration of 
thyroid hormone20, erythropoietin21,22, and acetylcholinesterase inhibitors.23,24 To further 
develop strategies that minimize cognitive side effects and to identify patients at risk, 
insight into the underlying pathophysiology of cognitive functioning during a course of 
ECT is needed. Known patient characteristics associated with cognitive functioning during 
or directly after ECT include poor baseline cognitive functioning and smaller hippocampal 
volume.9,25,26 Notably, no relation was found between age and cognitive functioning 
after ECT.8,27 In addition, several factors related to ECT administration were negatively 
associated with cognitive functioning during ECT, that is, bilateral electrode placement, 
brief pulse width and higher stimulus dose of ECT.10,28–30
The mechanisms by which change in cognitive functioning during and after a course of 
ECT may occur are largely unknown.31 One hypothesis is that cognitive functioning after 
ECT is impacted by larger temporary ECT-induced changes in hippocampus volume.32 
Another hypothesis is that there is an analogue with the pathogenesis of delirium: 
evidence from delirium research suggests that clinical factors such as inflammation, 
endocrine abnormalities, and oxidative stress can lead to transient disturbances in 
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cognitive functioning by interacting with pre-existent degenerative changes of the 
brain.33,34 Studies have found a relationship between increased levels of peripheral 
inflammatory markers, postoperative delirium and postoperative cognitive dysfunction.35 
We hypothesize that comparable mechanisms as in delirium influence cognitive 
functioning in depressed patients treated with ECT, and that the extent of the 
pre-existent inflammatory state of the depressed brain may further explain the 
variability in observed cognitive functioning prior to, during and after ECT. 
Aims of the study
This study aims to investigate whether an inflammatory profile relates to cognitive 
functioning prior to, during and directly after a course of ECT. We hypothesize that 
higher levels of inflammatory markers are associated with lower cognitive functioning 
during and after ECT. The Mood Disorders in Elderly treated with Electroconvulsive 
Therapy (MODECT) multicentre study provides an excellent opportunity to study the 
interplay between inflammatory markers and cognitive functioning in depressed 
persons. Previously it was shown that low-grade inflammation has a favourable effect 
on treatment response, e.g. moderately elevated CRP levels were associated with 
increased remission rates in depressed patients treated with ECT.36,37 Serum levels of 
C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10) and tumour necrosis 
factor-alpha (TNF-α) - biomarkers that to our knowledge have not been studied yet in 
relation to cognitive functioning during and after a course of ECT in a larger sample of 
older depressed patients - were chosen for further exploration. 
METHODS
Study sample
110 older (>55 years) patients were included in this naturalistic prospective 
cohort study. Patients were selected between January 2011 and December 2013 
from an inpatient population, referred for ECT, from the Department of Old Age 
Psychiatry of GGZ inGeest, Amsterdam, the Netherlands, and University Psychiatric 
Center KU Leuven, Belgium.38 Informed consent was obtained from all patients. 
The study protocol was approved by the ethical review board of the Amsterdam 
UMC and UPC Leuven and adhered the declaration of Helsinki. The clinical trial was 
registered at www.ClinicalTrials.gov with identifier: NCT02667353. Diagnosis of severe 
unipolar depression according to the DSM-IV was made by a psychiatrist and confirmed 
with the Mini International Neuropsychiatric Interview (MINI).39,40 Exclusion criteria were 
a major neurological illness including prior diagnosis of dementia. Patients with missing 
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Age, years, mean (SD) 73.1 (8.1)
Women, No. (%) 65 (67.0)
Level of education, years, median (IQR) 9.0 (3.0)
Inclusion site, Amsterdam/Leuven, No. 
(%Amsterdam)
54/43 (55.7)
Baseline MMSE, mean (SD), n = 82 24.1 (5.1)
MMSE after ECT, mean (SD) 26.2 (3.8)
Baseline MADRS, mean (SD) 33.8 (9.0)
Somatic morbidity
Cardiovascular diseases, No (%) 22 (23.4)
No. of chronic diseases, median (IQR) 1.0 (2.0)
Current smoking, No. (%), n = 82 21 (26.3)
Current alcohol use, No. (%), n = 91 24 (26.7)
ECT characteristics
ECT sessions, median (IQR) 11.0 (6.0)
Switch to bilateral ECT, No. (%) 29 (30.2)
Remission, No. (%) 64 (67.4)
Use of antidepressants, No. (%), n = 82 15 (18.5)
Use of antipsychotics, No. (%), n = 82 7 (8.6)
Biomarkers, median (IQR)
CRP, n = 90 1.7 (3.9)
IL-6, n = 91 2.7 (3.6)
IL-10, n = 93 0.9 (0.6)
TNF-_, n = 96 4.5 (1.7)
SD = standard deviation, IQR = inter quartile range, No. = number, MADRS =  
Montgomery Åsberg depression rating scale, CRP=C-reactive protein,  
IL-6 = interleukin-6, IL-10 = interleukin-10, TNF-α = tumour necrosis factor- α
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serum cytokine or CRP values were excluded from analysis (n=13). Attrition was not 
differential for age, sex, baseline depression severity, baseline cognitive functioning and 
level of education. 
Assessments
Global cognitive functioning was screened with the MMSE41, and was assessed prior to 
ECT, weekly during ECT and one-week after ECT (range 0-30). The outcome was defined 
as 1) the mean MMSE score one-week prior to the course of ECT, 2) the course of weekly 
MMSE scores during treatment, and 3) the mean MMSE score one-week after the course 
of ECT. 
Biomarkers
Marker selection was based on their relevance in previous studies on inflammation 
and depression. CRP is most widely used as a clinical marker for inflammation.42 Both 
IL-6 and TNF-α are widely used in psychiatric research as potential biomarkers involved 
in depression.43–45 IL-10 is an anti-inflammatory cytokine46 with strong deactivating 
properties of the inflammatory host response in case of excessive inflammation.47 IL-10 
is able to inhibit the production of proinflammatory cytokines such as IL-6 and TNF-α.46 
Serum samples were collected prior to ECT between 07h30 and 09h30 and were stored 
at -85°C until assayed. Analyses of inflammatory markers were performed as described 
before.36 In short, serum levels of CRP were determined with the High Sensitive (CRPhs) 
kit (Cobas CRPHA; Cat. No. 04628918 190). Serum levels of IL-6, IL-10 and TNF-α, were 
simultaneously determined using a 3-step multiplex digital immunoassay, the Simoa 
Human Cytokine 3-Plex A assay kit (Quanterix; cat.# 101160). Intra-assay and 
inter-assay reproducibility were 4.3% and 5.9% for IL-6, 3.9% and 5.3% for IL-10 and 
4.2% and 5.3% for TNF-α, respectively. All determinations were performed at the 
Clinical Chemistry department of Amsterdam UMC, Vrije Universiteit, Amsterdam, 
the Netherlands. 
Characteristics
Depressive symptoms were evaluated using the Montgomery Åsberg rating scale 
(MADRS, range 0-60).48 Remission was defined as a score < 10. Information on age, sex, 
inclusion site, the level of education in years, current smoking (yes/no), current 
alcohol use (yes/no) and somatic history including presence of cardiovascular diseases 
and the number of chronic diseases (cardiovascular disease, hypertension, chronic 
respiratory disease, diabetes mellitus, and arthrosis) were collected in a semi-structured 
interview. Antidepressant and antipsychotic medication use during ECT and 
 Inflammation and cognitive functioning  |  119
ECT characteristics  including electrode placement and the total number of treatment 
sessions were collected during treatment. 
ECT procedure
Brief pulse ECT was administered twice weekly using the Thymatron System IV 
(maximum energy 200%, 1008 mCoulombs) according to Dutch guidelines.49 
A titration protocol was used to determine the seizure threshold. Higher stimulus dose 
relative to seizure threshold is a risk factor for cognitive impairment28, therefore all 
patients received a stimulus dose six times the seizure threshold for unilateral stimulation 
and 2.5 times the seizure threshold for bilateral stimulation. Seizure duration shorter 
than 20 seconds (motor activity) or 25 seconds (EEG activity) was considered inadequate 
after which the dose was raised. Treatment was continued until remission was achieved 
or until there was no further improvement. Switch to bilateral stimulation (n=31) was 
made when no clinical improvement occurred after six right unilateral treatments or 
when clinical condition worsened, i.e. increased suicidality, dehydration or an increased 
MADRS score. Psychotropic medications were tapered off within two weeks prior to ECT 
or were kept stable during the ECT course if necessary. 
Statistical analyses
Baseline characteristics are reported as means with standard deviation (SD), median with 
interquartile range (IQR) and as percentages. In post hoc analysis, differences between 
patients with low and high levels of TNF-α were tested using independent samples t-tests, 
Mann-whitney U tests and χ2 tests. Statistical significance was set at p < 0.05. Normality 
(of the residuals) was assessed by the visual exploration of the data. Outliers were 
excluded according to Q1 – 3*IQR and Q3 + 3*IQR to avoid bias as a result of acute 
infection (CRP: n=7, IL-6: n=6, IL-10: n=4, TNF-α: n=1). Dichotomized values of the 
biomarkers - using the median value as the cut-off – were used to draw figures and 
to compare MMSE values within low and high inflammation groups. The mean MMSE 
values prior to and directly after a course of ECT were analysed using independent 
samples t-tests. We used a linear mixed model analysis to explore the association 
between biomarkers and longitudinal MMSE data (weekly scores) during treatment. The 
advantages of using a longitudinal mixed model instead of a linear regression analysis 
is that it allows for correlation between repeated measures, that is, inclusion of weekly 
MMSE scores rather than a change score, and it allows for multivariate analyses. After 
week seven most patients had finished ECT (84/97, 86.6%) and although mixed models 
are capable of processing missing values, the estimated models for week 8 and further 
are based on merely 13.3% of actual measures, therefore we used solely the first seven 
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weeks of MMSE measures. Subsequently, linear regression analysis was used to estimate 
the association between CRP, IL-6, IL-10 and TNF-α with cognitive functioning prior to 
and directly after a course ECT. All analyses were adjusted for age, sex, baseline MADRS 
score, and baseline cognitive functioning. All analyses were adjusted for cardiovascular 
diseases, smoking and alcohol use as lifestyle factors can be associated with inflammation 
and/or cognition.50–56 In the linear regression models, effect size (Cohen’s f2) was calculated 
from delta R2 and was interpreted as a small: f2 = 0.02, medium f2 = 0.15 or large 
f2 = 0.30 effect.57 No correction for multiple testing was applied as a clear a priori hypothesis 
was assessed.58 The explained variance was estimated in multivariate analyses. Sensitivity 
and specificity were calculated. Switching to bilateral electrode placement can result 
in decreased cognitive functioning during and after ECT10, therefore post hoc analysis 
was performed excluding all patients that switched to bilateral ECT during treatment. 
To rule out an influence of improvement of depressive symptoms on the association 
between inflammatory markers and cognitive functioning the interaction terms between 
inflammatory markers, remission, and change in MADRS were examined post hoc. If 
interaction terms were significant (p<0.1), analyses were repeated stratified. Multicollinearity 
was evaluated using Variance Inflation Factors (VIF) where a VIF > 2 indicates 
multicollinearity between covariates. Statistical analyses were performed using SPSS 
version 23 and STATA version 15.
RESULTS
In total, 97 patients were included in the analysis. The mean age was 73.1 years (SD ± 
8.1), Table 1. In total, 35.1% of patients (34/97) received bilateral ECT of which 88.6% of 
patients (30/34) after six unilateral sessions. Overall, 22 patients used either antipsychotic 
or antidepressant medication.
Cognitive functioning prior to a course of ECT
The mean MMSE score at baseline was 24.1 (SD ± 5.1) and was significantly lower in 
patients with higher levels of IL-6 (t=2.5, df 59.5, p = 0.02) and TNF-α (t=3.2, df 46.2, 
p=<0.01; Figure 1). In adjusted linear regression analysis, an association with a small 
to medium effect was found between higher levels of TNF-α at baseline and lower 
cognitive functioning prior to start of ECT: f2 = 0.06, see Table 2. No significant association 
was found with CRP, IL-6, and IL-10, and effect sizes were small: f2 = 0.05, 0.03 and 0.02 
respectively. The fully adjusted model including TNF-α explained 14.8% of the variance of 
cognitive functioning prior to a course of ECT (adjusted R2 = 0.148).
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Figure 1. Mean weekly MMSE scores during the first seven weeks of ECT in depressed, 
older patients, stratified for low and high levels of CRP, IL-6, IL-10 and TNF-α.
Cognitive functioning during ECT
Notably, a drop in MMSE is seen in Figure 1 at week 4 of treatment in patients with lower 
levels of TNF-α only. In linear mixed model analysis including the first seven weeks of 
ECT, adjusted for age, sex, depression severity, baseline MMSE scores, cardiovascular 
diseases, smoking and alcohol use, higher levels of IL-10 and TNF-α were associated with 
lower MMSE scores, see Table 2. 
Cognitive functioning directly after a course of ECT
The mean MMSE score directly after ECT was 26.2 (SD ± 3.8) and was significantly lower in 
patients with higher levels of IL-6 (t = 2.3, df 86, p = 0.03). We found a significant association 
between higher levels of CRP at baseline and cognitive functioning directly after a course 
of ECT in adjusted linear regression analysis: f2 = 0.10, see Table 2. The associations 
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between the baseline cytokine levels and cognitive functioning after ECT were 
nonsignificant and the sizes of the effect were small: IL-6: f2 = <0.01, IL-10: f2 = 0.04, 
TNF-α: f2 = 0.003. The fully adjusted model including CRP explained 24.9% of the variance 
of cognitive functioning directly after a course of ECT (adjusted R2 = 0.249). 
In post hoc analysis, patients that switched to bilateral ECT during treatment were 
excluded. The results remained similar for findings during ECT. The results after ECT 
altered slightly, that is, in the multivariate models, the association between 
IL-10, TNF-α and cognitive functioning altered to a significant association 
Table 2. Association between baseline biological markers and cognitive functioning in 
linear regression and mixed model analyses in older depressed patients receiving ECT
Univariate Multivariate
β (95% CI) p β (95% CI) 1 p
Prior to start of ECT
CRP -0.41 (-0.79 to -0.02) 0.04 -0.30 (-0.77 to 0.16) 0.2
IL-6 -0.29 (-0.59 to 0.01) 0.1 -0.18 (-0.62 to 0.26) 0.4
IL-10 -1.29 (-3.51 to 0.94) 0.3 0.08 (-2.48 to 2.62) 0.9
TNF-α -1.02 (-1.78 to -0.26) <0.01 -1.05 (-2.04 to -0.06) 0.04
During ECT
CRP -0.33 (-0.60 to -0.06) 0.02 -0.18 (-0.42 to 0.06) 0.1
IL-6 -0.22 (-0.43 to -0.00) 0.05 0.10 (-0.06 to 0.26) 0.2
IL-10 -2.85 (-4.44 to -1.26) <0.01 -2.08 (-3.22 to -0.95) <0.01
TNF-α -0.69 (-1.13 to -0.24) <0.01 -0.65 (-1.07 to -0.22) <0.01
Directly after a course of ECT
CRP -0.30 (-0.58 to -0.02) 0.04 -0.51 (-0.93 to -0.09) 0.02
IL-6 -0.15 (-0.39 to 0.08) 0.2 0.06 (-0.30 to 0.43) 0.7
IL-10 -1.98 (-3.64 to -0.33) 0.02 -1.84 (-3.82 to 0.14) 0.1
TNF-α -0.44 (-0.91 to 0.04) 0.1 -0.57 (-1.40 to 0.25) 0.2
1 adjusted for age, gender, depression severity at baseline, presence of cardiovascular 
disease, smoking, alcohol use and MMSE at baseline. Number of patients range from 
58 to 94 because of missing data for some covariates.
Abbreviations. CI = confidence interval, CRP=C-reactive protein, IL-6 = interleukin-6, 
IL-10 = interleukin-10, TNF-α = tumour necrosis factor- α
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(TNF-α: β = -1.18; 95%CI = (-1.48 to -0.88), f2 = 0.83, IL-10: β = -3.86; 95%CI = (-4.77 to -2.95), 
f2 = 0.87). Values for sensitivity and specificity did not exceed 80% for any of 
the inflammatory markers. No multicollinearity was found between covariates (VIF <2). 
No interaction effects were found between inflammatory markers and remission 
of depression, nor between CRP, IL-6, TNF-α and change in MADRS score both 
during and after a course of ECT. The interaction effect between IL-10 and 
change in MADRS score was significant. However, in stratified analysis, similar 
results were found, that is, no significant association was found between 
baseline IL-10 and cognitive functioning after a course of ECT. In post hoc 
analysis, similar remission rates were found between patients with low or high levels of 
TNF-α. Patients with higher levels of TNF-α were older and had more chronic diseases, 
see supplemental content. 
DISCUSSION
In this naturalistic cohort, we investigated whether higher levels of inflammatory markers 
are related to cognitive functioning. We hypothesized that inflammatory markers such as 
CRP, IL-6, IL-10 and TNF-α are associated with lower cognitive functioning in depressed 
patients treated with ECT. Previously, in this cohort it was shown that moderately elevated 
levels of CRP are associated with higher remission rates whereas IL-6, IL-10 and TNF-α 
are not.36 Here, we find that 1) higher levels of TNF-α are associated with lower cognitive 
functioning prior to the start of ECT, 2) higher baseline levels of IL-10 and TNF-α are 
significantly associated with lower cognitive functioning during the first seven weeks of 
ECT, even when controlling for baseline MMSE and 3) higher baseline levels of CRP are 
associated with cognitive functioning directly after a course of ECT. Patients with higher 
levels of CRP, IL-6, IL-10 and TNF-α only partially overlap. Our findings suggest that 
especially patients with higher levels of TNF-α not only experience a decreased 
cognitive functioning prior to the start of ECT but also are more vulnerable to lower cognitive 
functioning during a course of ECT. 
Cognitive symptoms in older depressed patients and inflammation
This is the first study to examine inflammatory markers and cognition in patients treated 
with ECT. Our finding that patients with higher levels of TNF-α are more likely to 
experience lower cognitive functioning prior to ECT suggests that severe depression with 
inflammation is associated with cognitive symptoms. Why do inflammatory depressed 
patients experience lower cognitive functioning? An analogy with the pathophysiological 
mechanism of delirium is proposed. Evidence from delirium research suggests that the 
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presence of inflammation can lead to disturbances in cognitive functioning by interacting 
with pre-existent degenerative changes of the brain and that peripheral inflammation 
can induce the release of inflammatory markers in the central nervous system.33,35 
In depression, the presence of low-grade peripheral inflammation in combination with 
degenerative changes (in older patients) or a pre-existent inflammatory state of the brain 
may explain the variability in observed cognitive symptoms in depressed patients. Our 
findings are in line with other studies in which an association between higher levels of 
inflammatory markers and cognitive impairment in older, healthy or depressed subjects 
was found.59–66 However, there are many conflicting reports showing a lack of association 
between inflammatory markers and cognitive impairment in older, healthy or depressed 
subjects.67–69 An explanation for the inconsistency in these findings could be the different 
composition of participants under study - for example, participants with less severe 
depressive symptoms - and different use of cognitive measures (global cognitive 
functioning scale versus specific cognitive domains). There are no comparable studies 
in older depressed patients treated with ECT. Our findings further strengthen the 
idea that cognitive functioning in older persons is influenced by an inflammatory 
process.
Cognitive side effects of ECT and inflammation
The mechanism by which cognitive side effects during and directly after a course of 
ECT occur is largely unknown. In contrast to our expectations, there was no decline in 
MMSE at group level during ECT. Our findings may suggest that depressed patients with 
higher levels of inflammatory markers are more vulnerable to lower cognitive 
functioning – although only small changes occurred - during and after a course of ECT. 
However, as this association was also found prior to ECT, it is difficult to arrive at any 
conclusions with regard to the effect of ECT on this association. 
Future implications
Monitoring inflammatory processes to predict cognitive functioning in depressed patients 
prior to and after a course of ECT seems possible based on the current data. Although 
the sensitivity and specificity when using inflammatory markers to predict cognitive 
functioning were low, the percentage of variance explained by the multivariate model was 
25%. Administration of anti-inflammatory medication during ECT can significantly reduce 
levels of TNF-α as is shown in patients with bipolar depression.70 If our findings are 
confirmed, such treatment strategies could be of additional value for improvement of 
cognitive functioning prior to, during and after a course of ECT. Future investigations of 
the  effect of anti-inflammatory treatment on cognitive functioning in depression are 
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merited. Moreover, to further explore whether changes in inflammatory markers 
during ECT affect cognitive functioning during and after ECT, future studies should 
include longitudinal measurements of inflammatory markers. Just like in delirium 
research34 multiple pathways may be complementary in cognitive functioning in 
depressed patients. Therefore, a suggestion for future studies may be to combine 
inflammatory markers with other (imaging) biomarkers in developing a combined risk 
score for lower cognitive functioning during and after a course of ECT. In addition, to 
further explore whether changes in cognitive functioning are driven by specific cognitive 
domains, future studies should include more specific and sensitive neuropsychological 
instruments rather than solely the MMSE.  
Limitations
Notably, the following strengths and limitations should be considered. The prospective 
study design allowed us to collect a substantial set of clinical data from which putative 
confounders were selected. We used the MMSE – widely used to measure global 
cognitive functioning - as a scale to measure cognitive functioning. It has shortcomings 
such as test-retest effects, a ceiling effect, the lack of ability to assess specific cognitive 
domains, and it may lack sensitivity to detect small changes, especially in patients with 
vascular brain changes.71–75 Despite the ceiling effect, we found a significant association 
between inflammatory markers and cognitive functioning suggesting the effect may be 
larger if we had used a more sensitive test. Moreover, one of the difficulties in 
investigating cognitive functioning during ECT is the influence of depression itself on 
cognitive performance. In this study, the influence of ECT on cognitive functioning may 
be underreported because of the synchronous improvement of depressive symp-
toms and cognition.76 This study used pre-ECT inflammatory markers to investigate the 
association with cognitive functioning pre-, during and after ECT. Including longitudinal 
inflammatory biomarkers would have allowed us to control for depression-related 
changes in inflammation. Also, it is to be determined whether the differences in weekly 
MMSE scores between patients with lower and higher inflammatory markers (ranging 
from 0.5 to 2.5 points) is of clinical relevance to patients. No corrections for multiple 
testing were performed and, although the analysis were all hypothesis driven, this still 
may have affected the type I error of this study. Finally, other factors may impact on 
cognition such as anaesthesia itself9, pulse width77, and stimulus dose of ECT.28 To 
minimize the influence of these factors on our findings, all patients received equal ratios 
of stimulus dose relative to seizure threshold and all received brief pulse ECT. 
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Conclusion
Previously low-grade inflammation was found to be associated with increased remission 
rates in our sample of 97 depressed older patients treated with ECT. This current study 
suggests that baseline inflammatory processes are associated with lower cognitive 
functioning prior to ECT (TNF-α), and predispose for (further) cognitive dysfunction 
during (TNF-α and IL-10) and after (CRP) a course of ECT. Future studies could provide 
more in-depth on the role of inflammation on the cognitive symptoms of depression, 
and the effectivity of (add-on) anti-inflammatory treatment to improve these symptoms 
during an ECT course.
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SUPPLEMENTAL MATERIAL
Supplemental Table. Group characteristics of older depressed patients with low  
(< 4.48 pg/ml) or high levels of TNF-α treated with ECT (n = 96).
Low TNF-α High TNF-α
n = 56 n = 40 p
Socio-demographics
Age, years, mean (SD) 70.8 (7.7) 76.4 (7.7) <0.01
Women, No. (%) 36 (64.3) 29 (72.5) 0.4
Baseline MMSE, mean (SD), n = 81 25.5 (3.9) 21.7 (5.9) <0.01
MMSE after ECT, mean (SD) 26.8 (3.6) 25.4 (4.0) 0.1
Baseline MADRS, mean (SD) 33.9 (8.1) 33.7 (10.3) 0.9
Remission, No. (%) 39 (69.6) 25 (64.1) 0.6
Somatic morbidity
Cardiovascular diseases, No (%) 9 (16.4) 13 (33.3) 0.1
No. of chronic diseases, median (IQR) 1.0 (1.0) 1.0 (1.0) 0.02
Current smoking, No. (%), n = 82 13 (30.2) 8 (21.6) 0.4
Current alcohol use, No. (%), n = 91 15 (27.3) 9 (25.7) 0.9
ECT characteristics
ECT sessions, median (IQR) 10.5 (6.0) 11.5 (7.0) 0.8
Switch to bilateral ECT, No. (%) 15 (26.8) 14 (35.0) 0.6
Use of antidepressants, No. (%), n = 82 7 (16.3) 8 (21.1) 0.6
Use of antipsychotics, No. (%), n = 82 3 (7.0) 4 (10.5) 0.6
SD = standard deviation, IQR = inter quartile range, No. = number, MADRS =  
Montgomery Åsberg depression rating scale, TNF-α = tumour necrosis factor- alpha
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IMPACT OF INFLAMMATION ON COGNITIVE 
FUNCTIONING AFTER ELECTROCONVULSIVE 
THERAPY IN OLDER DEPRESSED 






Should we treat older, depressed patients with white matter hyperintensities (WMH) with 
electroconvulsive therapy (ECT)? WMH, inflammation, depression and cognitive functioning 
are suggested to be intertwined. Hence, this study investigates whether the presence of 
WMH alters the association between inflammatory markers and cognitive functioning in 
depressed patients treated with ECT. 
Methods 
Cognitive functioning was screened using the Mini-Mental State Examination after a 
course of ECT in 79 older depressed patients. Serum samples (C-reactive protein [CRP], 
interleukin-6 [IL-6], interleukin-10 [IL-10] and tumour necrosis factor-alpha [TNF-α]) and 
3T magnetic resonance imaging were obtained in the week before the start of ECT. 
Results
In linear regression analyses, stratified for presence of moderate to severe WMH, both 
IL-10 and TNF- α were significantly associated with lower cognitive functioning in patients 
with WMH. 
Conclusions 
These findings suggest that patients with WMH are more vulnerable to lower cognitive 
functioning after ECT when inflammation is present. 
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INTRODUCTION
Should we treat older, depressed patients with white matter hyperintensities (WMH) 
with electroconvulsive therapy (ECT)? ECT is the most effective treatment for 
depression1, however, practitioners are often reluctant to start ECT because of the 
risk of transient2 cognitive effects after a course of ECT. Previously, in this cohort3, a 
relationship was found between higher baseline levels of inflammatory markers and 
lower cognitive functioning in older depressed patients before, during and after 
electroconvulsive therapy (ECT). In line with these findings, although still inconclusive, 
studies suggest an association between cognitive functioning and inflammation in both 
depressed and healthy persons.4 A potential underlying factor linking inflammation 
with cognition might be white matter pathology as studies have found associations 
between WMH, cognitive functioning and depression5,6, as well as between WMH and 
inflammation. For example, in post-operative delirium research, it was found that 
patients with pre-operative WMH had an increased risk of developing delirium7, which 
is a disorder characterized by temporary profound changes in cognitive functioning, 
suggesting that a brain with WMH is more vulnerable to inflammation. 
Here, we expand on our earlier findings and investigate whether, in older depressed 
patients, the association between inflammatory markers and cognitive functioning 
is different for patients with moderate to severe WMH. For many practitioners, the 
cognitive side effects of ECT remain a concern. Hence, it is particularly interesting to 
explore the association between inflammatory markers and cognitive functioning 
directly after a course of ECT in an ECT cohort with older depressed patients. A better 
understanding of the underlying factors contributing to lower cognitive functioning may 
lead to potential targets for prevention. 
METHODS
Study overview 
Data were collected from two psychiatric hospitals, GGZ inGeest in the Netherlands, 
and the University Psychiatric Center KU Leuven in Belgium. All included patients were 
diagnosed with unipolar major depression, aged 55 years and older and referred for 
ECT. Excluded were patients with a history of major neurological illness including stroke 
and dementia. All procedures involving patients were approved centrally by the Ethical 
Review Board of the Amsterdam University Medical Centre and subsequently by the 
ethical review board of the Leuven University Hospitals. Written consent was obtained 
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from all participants. Here we present data from a subgroup (n=79) from a previously 
described cohort study.7 The median number of ECT administrations was 11.0 
(interquartile range: 6.0). ECT was continued until a Montgomery Åsberg Depression 
Rating Scale score of less than 10 was reached at two consecutive ratings or until no 
further improvement in clinical condition was seen after at least six unilateral and six 
bilateral ECT sessions. 
Inflammatory markers 
The selection of potential relevant inflammatory markers is based on availability and 
findings on the relevance of these markers in studies to date. Serum cytokine and 
C-reactive protein (CRP) levels were measured in the week before the start of ECT. 
Interleukin-6 (IL-6), interleukin-10 (IL-10) and tumour necrosis factor-alpha (TNF-α) were 
determined using the Simoa Human Cytokine 3-Plex immunoassay. CRP was determined 
using the Cobas CRPHA kit. All determinations were performed at the Clinical Chemistry 
department of Amsterdam UMC, Vrije Universiteit, Amsterdam.
Cognitive functioning 
Cognitive functioning was screened using the Mini-mental State Examination (MMSE, 
score range 0-30) directly after a course of ECT, e.g. one week after the last ECT session. 
White matter hyperintensities 
MRI was performed prior to ECT. Structural WMH were rated using the Age-Related White 
Matter Changes (ARWMC) scale as the sum score of ten brain regions, subsequently 
ranked in two groups: 1) no or few structural white matter hyperintensities (WMH; score 
0-9) and 2) moderate to severe WMH (score 10-30). All MRI images were rated by an 
independent neuroradiologist.
Statistical analyses 
The association between inflammatory markers and MMSE score was investigated using 
linear regression analyses and was stratified for the presence of WMH. All analyses were 
adjusted for age, gender, baseline depression severity, baseline cognitive functioning, 
years of education, smoking, alcohol use and presence of cardiovascular diseases. 
Results are reported as β-coefficient with a 95% confidence interval (CI). A p-value <0.05 
was considered significant. 
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RESULTS
The mean age of the sample was 72.9 years (SD±8.4). Patients without structural WMH 
(n=52) had a mean MMSE score of 26.8 (SD±3.5) directly after a course of ECT compared 
to a mean score of 25.0 (SD±4.6) in patients with structural WMH (n=27). In fully adjusted 
linear regression analyses, stratified for presence of structural WMH, both IL-10 and TNF- α 
were significantly associated with lower cognitive functioning directly after a course of 
ECT in patients with WMH (IL-10: β = -4.11 [CI: -6.43; -1.79], TNF-α: β = -2.57 [CI: -4.05; 
-1.08]). This association was not found for any of the inflammatory markers and cognitive 
functioning in patients without WMH, see Table 1. The association between CRP prior to 
ECT and cognitive functioning after ECT in patients with WMH lost its significance after 
adjustment for possible confounders including the presence of cardiovascular diseases. 
Table 1. Linear regression analyses. Association between inflammatory markers and 
cognitive functioning directly after a course of ECT divided in patients with no or few 
structural white matter hyperintensities (WMH) (n=52) and patients with moderate to 
severe WMH (n=27), in older depressed patients.
Predictor variable Univariate Multivariable
β (95% CI) p β (95% CI) p
No structural WMH
     CRP -0.04 (-0.41 to 0.33) 0.8 -0.18 (-0.75 to 0.39) 0.5
     IL-6 -0.05 (-0.36 to 0.26) 0.7 -0.05 (-0.46 to 0.56) 0.8
     IL-10 -0.81 (-2.94 to 1.31) 0.5 -1.17 (-3.37 to 1.02) 0.3
     TNF-α -0.07 (-0.55 to 0.69) 0.8 0.36 (-0.73 to 1.46) 0.5
Moderate to severe 
WMH
     CRP -0.75 (-1.38 to -0.11) 0.02 -0.60 (-1.34 to 0.15) 0.1
     IL-6 -0.62 (-1.27 to 0.04) 0.1 -0.61 (-1.35 to 0.14) 0.1
     IL-10 -4.26 (-7.46 to -1.06) 0.01 -4.11 (-6.43 to -1.79) <0.01
     TNF-α -2.02 (-3.19 to -0.85) <0.01 -2.57 (-4.05 to -1.08) <0.01
Multivariable model: adjusted for age, gender, years of education, MMSE at baseline, 
depression severity at baseline, presence of cardiovascular disease, smoking and 
alcohol use.
CI = confidence interval, CRP = C-reactive protein, IL-6 = interleukin-6, IL-10 =  
interleukin-10, TNF-α = tumour necrosis factor-α
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CONCLUSIONS
Previously, we suggested that ECT is more effective in patients with signs of 
inflammation (CRP levels 3 to 10 mg/L).9 In addition, in the same cohort, we found that 
patients with higher levels of several inflammatory markers prior to ECT showed lower 
cognitive functioning both before, during and after a course of ECT in depressed 
older patients (Carlier et al - submitted). With the present study, we wanted to investigate 
whether the association between cognitive functioning and inflammation is different for 
patients with or without WMH. 
Our findings suggest that WMH form an underlying factor in the relationship between 
inflammation prior to ECT and cognition after a course of ECT. No association was found 
between inflammatory markers prior to ECT and cognitive functioning after a course of 
ECT in depressed patients without white matter hyperintensities further strengthening 
this hypothesis. In line with our findings, two previous studies have described a lower 
cognitive function in depressed patients with WMH, although cognitive functioning 
was measured during ECT.10,11 These findings suggest that patients with white matter 
hyperintensities are more vulnerable to lower cognitive functioning after ECT when 
inflammation is present, whereas older depressed patients with inflammation tend to 
have higher remission rates, as mentioned above.9 In addition, patients with WMH have 
similar response and remission rates as patients without WMH12, therefore the presence 
of WMH does not oppose ECT. Further research is needed to determine whether 
these findings can be utilized in the prevention of cognitive symptoms in depression 
and/or cognitive effects in ECT. Limitations of this study are the use of the MMSE to 
measure cognitive functioning as it has a known ceiling effect and test-retest effects. 
In addition, adjustment for cardiovascular diseases and smoking may have caused an 
underestimation of the association between inflammation and cognitive functioning.
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This thesis’s main objective was to expand current knowledge on biomarkers in 
ECT-treatment to contribute to future personalized treatment of late-life 
depression. The first part of this work examined the pattern of biomarkers 
during a course of ECT and the association between biomarkers and treatment 
outcome. The second part explored the association between inflammatory markers, 
cognitive functioning, and white matter hyperintensities. In the past 30 years, over 
8000 studies concerning ECT have been conducted. Still, at present, we cannot 
distinguish which persons will respond to antidepressant medication or ECT, resulting 
in a stepwise treatment protocol similar for all depressed patients. ECT is 
recommended in depressed persons only after two trials of antidepressants 
have failed 1. In this thesis, we explored whether biomarkers can assist in identifying 
patients that are more likely to respond to ECT and are more likely to experience 
cognitive side effects. The main results are summarized and discussed below. Finally, 
methodological considerations, implications for clinical practice, and recommendations 




One biomarker of interest included in this work was S100 calcium-binding protein 
(S100B). S100B is a protein that is expressed by microglial cells (astrocytes and 
oligodendrocytes) and has various functions in neuronal plasticity and apoptosis. It can 
be used as a marker of neuroplasticity.2 Increasingly, it is thought that neuroplasticity 
is disrupted in depression.3–5 S100B is suggested as a biomarker indicative of 
depression (a disease state marker), as it is found elevated in episodes of major 
depression.6,7 Neuroplasticity, on the other hand, is also considered a potential working 
mechanism of ECT. Volume increases in the hippocampus, amygdala and cingulate 
cortex have been observed after ECT.8–10 In Chapter 2 we investigated whether S100B 
was a state marker of depression and whether it was associated with favourable ECT 
outcome within the MODECT cohort of 110 older depressed patients receiving ECT. 
Changes in pre- and post-ECT levels of S100B were compared between remitters and 
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nonremitters. Logistic and Cox regression analyses were used to determine whether 
S100B was associated with remission of depression. There was no significant decrease 
in levels of S100B after ECT in both remitters and nonremitters, which made it less likely 
that S100B was a state marker of depression. Patients with intermediate levels of S100B 
(between 33 ng/L and 53 ng/L) before ECT had favourable treatment outcome compared 
to patients with lower or higher levels of S100B. They were also more likely to remit from 
depression over time. Despite the association between S100B and remission, sensitivity 
and specificity were low, therefore, S100B is not considered an eligible biomarker of ECT 
outcome. 
Inflammation
Other biomarkers of interest included in this work were inflammatory markers. 
When peripheral inflammatory markers cross the blood-brain barrier, they can 
activate microglia, and, therefore, may impact both neuroinflammation and 
neuroplasticity.11,12 Over the past years, compelling evidence has associated depression 
with inflammation. First, higher levels of inflammatory markers are found in patients 
with depression.13–21 In late-life depression in specific, inflammatory markers are 
found in nearly half of the patients.22 Second, it is suggested that markers of 
inflammation play a role in the pathophysiology of depression as they activate microglia 
who in their turn promote neuroinflammation, oxidative stress and activate the 
kynurenine pathway.11,12,23,24 The kynurenine pathway can cause neurotoxicity and is 
often found activated in depressed patients.11 Third, findings suggest an association 
between peripheral inflammatory markers and treatment response25–27 or treatment 
non-response.28,29 In Chapter 3, we investigated whether there was an association 
between pre-treatment levels of inflammatory markers and ECT outcome. We 
found that moderately elevated levels (3 to 10 mg/L) of CRP were associated with 
higher remission rates of depression and an increased speed of symptom decline after 
ECT. A remission rate of 83.9% in patients with a CRP of 3 to 10 mg/L was found 
comparedwith a remission rate of 61.1% in those with CRP levels lower than 3 mg/L. 
Per ECT session we estimated a decline of 3.2 MADRS points (Montgomery Åsberg 
Depression Rating Scale) in the moderately elevated CRP group compared to 
2.3 MADRS points in the low CRP group. No consistent associations were found 
between IL-6, IL-10, TNF-α and ECT outcome. We concluded that older depressed 




Subsequently, we were interested in whether ECT has an anti-inflammatory effect. 
Previous studies found an increase in leucocytes, interleukin-1 and IL-6 after a single 
ECT administration suggesting an acute immune response.30–32 After repeated ECT 
administrations, although the number of studies was limited, levels of interleukin-5, IL-6, 
and TNF-α tended to fall.30,32 To investigate whether ECT has an anti-inflammatory effect, 
we examined changes in inflammatory markers during and after ECT. In Chapter 4, the 
pattern of CRP, IL-6, IL-10, and TNF-α was examined among depressed older patients 
in the MODECT study. Small to medium effect sizes were found for a decrease in CRP 
and IL-6 after ECT. No differences were found in the pattern of inflammatory markers 
between responders and non-responders, and between remitters and non-remitters of 
depression. We concluded that a possible decrease in inflammatory markers after ECT is 
not associated with ECT outcome and that the anti-inflammatory effect of ECT could not 
be confirmed. 
Apathy
Late-life depression has been associated with white matter changes33 and white matter 
changes in turn have been associated with apathy.34–36 Despite the overlap between 
motivational symptoms of depression and apathetic symptoms, apathy is considered 
an independent behavioural syndrome.37 Apathy is a known contributing factor to a 
decreased quality of life.38 In Chapter 5 we investigated whether there was an association 
between vascular burden and the course of apathy in 73 apathetic patients treated 
with ECT within the MODECT study. Vascular burden included the presence of vascular 
disease, diabetes mellitus, smoking, and white matter hyperintensities. MRI data on 
white matter hyperintensities were available in 52 patients only. After ECT, 50 patients 
(68.5%) remitted from depression. Of these 50 patients, 52.0% still suffered from 
clinically evident apathy. Of the patients that did not remit from depression (n=23), 78.3% 
experienced apathy. No association was found between persistent apathy and vascular 
burden. First, we concluded that apathy may not be relieved by successful treatment 
with ECT and needs a distinctive approach. Second, the persistent apathy symptoms 
measured in our cohort might have been, in some patients, residual symptoms of 
depression. Finally, we concluded that apathy in depressed patients may be different 
from apathy in non-depressed patients as, in contrast to other studies, we found no 
association between vascular burden and apathy. This idea is strengthened by studies 
suggesting a strong link between higher levels of CRP and apathy in non-depressed 
patients39 but not in depressed patients.40 
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PART II:
Biomarkers and cognition
Apart from examining ECT outcome such as remission, getting closer to personalized 
depression treatment also involves investigating the side effects of ECT. For many 
ECT practitioners, cognitive side effects after ECT remain a concern. In Chapter 6, we 
examinedwhether inflammatory markers could help us to identify which patients 
are more prone to developing cognitive side effects during and after ECT. 
Cognitive functioning was assessed with the Mini-Mental State Examination (MMSE). 
Pre-treatment inflammatory processes were associated with lower cognitive functioning 
prior to ECT (TNF-α). As this association was present before start of ECT, we were 
unable to disentangle the explicit influence of inflammatory markers on cognitive 
functioning during and after ECT. In line with our findings, a known risk factor for 
lower cognitive functioning during and after ECT is poor baseline cognitive 
functioning.41,42 Previous studies suggested an association between cognitive 
impairment and higher levels of inflammation in older, healthy or depressed subjects.43–47 
We suggested that similar processes are involved in cognitive functioning during 
ECT, that is, that lower cognitive functioning pre-ECT is associated with higher 
levels of inflammation. These patients are subsequently predisposed for cognitive 
dysfunction during and after a course of ECT, although the attributable effect of ECT 
remains uncertain. 
Apart from the link between inflammation and cognition, studies have suggested a link 
between lower cognitive functioning, depression and white matter hyperintensities.48 
Therefore, to expand the findings of Chapter 6, we investigated whether the presence 
of white matter hyperintensities altered the association between inflammatory markers 
and cognitive functioning in older depressed patients treated with ECT (Chapter 7). 
To specifically examine ECT influences, we looked at cognitive functioning after ECT 
for this analysis. In stratified linear regression analyses, both higher levels of IL-10 and 
TNF-α pre-ECT were associated with lower cognitive functioning after a course of ECT in 
patients with white matter hyperintensities, compared with no association in patients 
without white matter hyperintensities. We concluded that patients with white matter 
hyperintensities are more vulnerable to lower cognitive functioning after ECT only 
when inflammation is present. 
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Overall conclusions
The main objective of this thesis was to expand current knowledge on biomarkers in 
ECT-treatment to contribute to future personalized treatment of late-life depression. 
The first part aimed to explore biomarkers and treatment outcome. The second part 
aimed to explore biomarkers and cognitive functioning. We can conclude that older 
depressed patients with a profile of low-grade inflammation or intermediate levels of 
S100B who receive ECT have higher chances of remission of depression. However, we 
also conclude that both CRP and S100B are not eligible biomarkers for ECT outcome as 
their sensitivity and specificity were low. In general, a useful biomarker should have a 
sensitivity (for detecting therapy outcome) and a specificity (for discriminating 
between outcomes) of at least 80%.49 Vascular brain changes, that is, white matter 
hyperintensities, are not associated with persistent apathy after ECT. Higher levels 
of inflammation before start of ECT are associated with lower cognitive functioning. 
This association remains during and after ECT, however, it seems that patients with 
inflammation and white matter hyperintensities are in particular vulnerable to 
developing lower cognitive functioning after ECT. 
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METHODOLOGICAL CONSIDERATIONS
This thesis is based on the Mood Disorders in Elderly treated with ECT study (MODECT), 
a multi-site, naturalistic, prospective cohort study on older (>55 years) patients treated 
with ECT. Strengths of the MODECT are its relatively large sample of clinical patients 
with a major depressive disorder (n=110) and its comprehensive set of data including 
brain imaging and blood samples. A few considerations have to be kept in mind when 
interpreting the findings of this thesis. Generalization of these results towards younger 
patients, outpatients or patients with mild or moderate depression is not indisputable. 
Moreover, the study may lack power when comparing subgroups of patients.
Next, within MODECT, the collection of a substantial set of clinical data allowed us to 
adjust for putative confounders, nonetheless, the risk of residual confounding has to be 
considered in observational cohort studies. Moreover, psychotropic medication could 
not be tapered off in all patients causing a possible confounding effect albeit inconsistent 
findings exist on whether psychotropic medication influences inflammation50 and levels 
of S100B.51 Likewise, MODECT was not primarily set-up for inflammatory research, 
therefore, data on the concurrent use of anti-inflammatory medication is missing. In 
addition, body mass index-data was absent in nearly half of the patients and 
comprehending that adipose tissue is highly correlated with levels of S100B52 and 
circulating levels of inflammatory cytokines53 this limits our findings. Moreover, acute 
infections in patients were not reported. To exclude these patients, we have excluded 
timepoint samples with CRP levels that were three standard deviations above and below 
interquartile range or CRP levels above 10 mg/L, as is best practice in scientific literature.54 
In the concerning studies (Chapters 3,4, and 6), analyses are reported both with and 
without extreme values to give a complete image of the data. 
Some of the measures used in MODECT should be reconsidered for future research. 
For example, the Apathy Scale by Starkstein et al.55 is validated in older patients with 
dementia and Parkinson’s disease, but not in patients with depression. An alternative 
could be the Apathy Evaluation Scale by Marin et al.56 In addition, the Mini-Mental State 
Examination57 measures global cognitive functioning but has shortcomings such as not 
being able to distinguish between different cognitive domains and it may lack sensitivity 
to detect small changes.58,59 
We should note that the biomarkers described in this thesis indicate peripheral 
inflammation and not central inflammation. Studies measuring levels of inflammation 
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in cerebrospinal fluid (csf) are scarce, however, studies have found increased levels of 
inflammation in csf60 and a high correlation between levels of peripheral CRP and csf 
CRP in depressed patients61 suggesting that peripheral markers can indicate central 
inflammation. In this study, circulating inflammatory markers were measured which 
indicate the presence of inflammation over a prolonged period.62 Levels of circulating 
inflammatory markers are thought to be less affected by genetic factors than stimulated 
inflammatory markers.63,64 The latter provides information on a patient’s cytokine 
production capacity. It is important to keep in mind that cytokine levels show a high 
degree of heterogeneity across studies28,29 because they are sensitive to multiple outside 
signals such as disease, infection, and smoking behaviour. A recent study has 
meta-analyzed this variability in patients with depression; IL-6 and TNF-α variability was 
similar for controls and depressed patients.21 Variability of CRP in depressed patients, 
however, was significantly reduced compared to controls suggesting CRP to be a rather 
homogenous inflammatory marker in depression. 
Regarding longitudinal follow-up, it should be considered that in the apathy study 
(Chapter 5), we were unable to include 4-week follow up measurements because of high 
numbers of loss to follow up (62%). Future research should examine longer periods after 
ECT to examine whether apathy is a residual symptom of depression. 
Finally, for every study, a consideration was made whether to correct for multiple 
testing. In Chapters 3, 6, and 7, no correction for multiple testing was made, even though 
the analyses included four biomarkers (CRP, IL-6, IL-10, TNF-α). By making this decision, 
the risk of a type-I error (rejecting a true null-hypothesis) increased.66 To support our 
findings, effect sizes were calculated in Chapters 3 to 6 using Cohen’s f2 or Cohen’s d.67 
 General discussion  |  151
IMPLICATIONS FOR CLINICAL PRACTICE AND THEORY
This thesis aimed to explore the association between biomarkers and ECT outcome, and 
biomarkers and cognitive functioning, and to expand knowledge for future personalized 
treatment of late-life depression. 
Theory on antidepressants versus ECT
Studies involving untreated patients or patients receiving antidepressant medication 
found associations between levels of inflammation, persistence of symptoms, and 
treatment resistance.28,68,69 A recent meta-analysis regarding 15 inflammatory 
markers found no, except one, associations between inflammatory markers and 
response to antidepressants.29 Our study found no association with treatment resistance. 
In contrast, we found an association between inflammation and favourable ECT 
outcome. Other studies found a better ECT outcome in patients with higher levels of IL-670 
or TNF-α.71 These findings may suggest that patients with higher levels of inflammation 
are more likely to respond to ECT than to antidepressant medication. Currently, 
treatment of depression follows a stepped-care model. A more personalized approach 
would be to use a stratified care plan in which treatment modalities are chosen based 
on biomarker profile. An example of a stratified care plan is given in Figure 1. However, 
it should be kept in mind that the inconsistencies between findings from antidepressant 
medication trials and ECT trials may also be explained by the different patients under 
study. Patients receiving ECT are frequently patients with treatment-resistant and severe 
depression which can influence levels of inflammation, and therefore may confound the 
findings from antidepressant- and ECT trials. Consequently, our findings only apply to 
depressed patients from a population comparable to the one in this thesis. Randomized 
studies including depressed patients with and without inflammation receiving different 
treatment modalities are necessary before a stratified care model can be realized. 
We demonstrated that remitters of depression had higher levels of CRP before start 
of ECT. It has long been thought that depression is a heterogeneous disorder and that 
different subtypes require different treatment approaches. Our findings may suggest 
that inflammatory subtypes of depression respond well to ECT. One previously proposed 
subtype in depressed adults is the immune-metabolic subtype; a subtype related to 
inflammatory markers, female gender, higher BMI, metabolic syndrome  , and atypical 
symptoms of depression (weight gain and increased appetite).68,72–78 These ‘atypical’ 
symptoms of depression are less prevalent in older persons than in adults.74,79,80 In 
addition,as predictors of ECT response include ‘typical’ (melancholic) symptoms of 
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depression such as decreased appetite, hyposomnia and psychomotor retardation, 
patients referred for ECT can be expected to have more melancholic symptoms than 
patients in studies involving other treatment modalities. Therefore, the patients under 
study in this thesis may differ from the patients in the above mentioned studies and 
may share another immunological subtype of depression than the immune-metabolic 
subtype. To find out if the patients receiving ECT have the same depression subtype as the 
immune-metabolic patients, further research is needed. A recent study by Lynall et al.81 
suggests that separate subgroups exist within the inflammatory subtype. They found two 
subgroups, both with higher levels of CRP and IL-6, however, with different immune cell 
profiles. Group 1 showed higher numbers of adaptive immune cells (T cells and B cells), 
for example, memory cells reacting to previously experienced stress or infection. Group 2 
showed higher numbers of innate immune cells (monocytes and neutrophils), that is, an 
Stepped Care
Stratified Care











Figure 1. An example of an older patient following a stepped care or a (hypothetical) 
stratified care plan in which treatment modalities are chosen stepwise or based on 
biomarker profile. 
* These findings apply only to older patients with severe depression comparable with the 
population in this thesis, findings need replication
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acute reaction to stress or infection. These findings suggest that different aetiologies may 
account for different immunological subtypes of depression. 
Although our findings suggest that patients with higher levels of inflammation tend to 
respond well to ECT, we could not confirm an anti-inflammatory effect of ECT. Newer 
antidepressant treatments such as add-on infliximab, minocycline25,82, and ketamine 
appear to have more anti-inflammatory properties and should therefore be included 
in further research regarding immunological subtypes of depression. As an example, 
a trial will start soon at the Amsterdam University Medical Center, where patients with 
the immune-metabolic subtype of depression will be treated with the anti-inflammatory 
medicine Celecoxib. So, why do we think that patients with higher inflammatory markers 
respond well to ECT? Maybe increased inflammation in depressed patients merely 
reflects older age83, more severe depression84 or psychomotor retardation85, all factors 
associated with better ECT outcome. Another possibility is that ECT does have a central 
anti-inflammatory effect that is not observed in our peripheral measurements. Kranaster 
et al.86 found a decrease of an innate immunity regulator protein (MIF) in the csf of 
patients that remitted from ECT suggesting a reduction in central cytokine production 
after a course of ECT. Furthermore, they found that patients with increased levels of 
baseline sCD14 - a marker of glial activation - had higher chances of responding to ECT 
similar to our finding of S100B. This may suggest that glial activity and immune cell 
activity pre-ECT is beneficial in further treatment, though the mechanism behind this 
benefit remains unknown. 
Subsequently, our study demonstrated a link between cognition and inflammation in 
depressed patients with or without treatment of ECT. Previous research has found that 
patients with white matter hyperintensities have similar remission rates as patients 
without white matter hyperintensities87 and patients with higher inflammation have even 
higher remission rates after ECT70,71 despite the increased risk of lower cognitive functioning. 
The mechanism behind inflammation, cognition and white matter hyperintensities is 
unknown. We propose a possible analogy with delirium, a disorder where disturbances in 
cognitive functioning are caused by inflammation interacting with degenerative changes 
in the brain (for example, an ageing brain).88,89 Assumed that this hypothesis is correct, 
it is possible that in older depressed patients, lower cognitive functioning is caused 
by a pre-existent (possibly caused by depression) inflammatory state of the brain. As 
described earlier, peripheral inflammatory factors can induce microglial cytokine 
production causing neuroinflammation.11 Inflammatory markers on the brain side 
of the blood-brain barrier (BBB) can weaken BBB integrity65,90, therefore, patients with 
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pre-existent inflammation may have a different crossover of immune cells during ECT 
compared with patients with an intact BBB possibly causing more cognitive symptoms. 
As for clinical implications, monitoring inflammatory processes to predict cognitive 
functioning in depressed patients prior to and after a course of ECT seems possible based 
on the current data. In addition, monitoring inflammatory processes during depression 
can assist in understanding, and possibly treating, observed cognitive symptoms. 
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FUTURE RESEARCH
Our study demonstrated higher remission rates in patients with moderately elevated 
levels of CRP and intermediate levels of S100B. Previous research in turn suggested older 
age, psychomotor symptoms and psychotic symptoms as features associated with 
remission.71,91,92 Therefore, a future step could be to see whether these features combined 
reach a reasonable test sensitivity and specificity to be able to predict ECT outcome. 
Also, a large number of patients does not respond to the current existing treatments for 
depression. Several studies have identified differential symptom clusters of 
depression74,80,93,94, nevertheless, studies still tend to include heterogeneous samples of 
depressed patients also because inconsistent symptom clusters are found across 
studies.95,96 The previously mentioned subtypes were all identified using latent class 
analysis. Other techniques have been used such as machine learning allowing for large 
data samples and low costs.93 For example, national electronic health records could be 
used in the future to identify symptom clusters in depressed patients receiving ECT and 
their outcomes. 
Next, it would be of interest to investigate the prevalence of different symptom clusters 
across different age groups. For example, as low-grade inflammation has been associated 
with older age63, inflammatory symptom clusters may be more common in late-onset 
depression. Moreover, studies should investigate the effectiveness of medication and 
ECT in several subtypes of depression, for instance, by clustering depressive symptoms 
and randomly assigning patients to treatment modalities including placebo, an SSRI and 
ECT. An example of a similar type of study is that of Bondar et al.97 who identified two 
symptom clusters in depressed adolescents, of which one symptom cluster responded 
to psychotherapy and fluoxetine and the other symptom cluster did not, both in 
comparison to placebo. 
Another step would be to perform clinical trials and cohort studies within different 
symptom clusters of depression. For example, low-grade inflammation (CRP > 3mg/L) 
occurs in 27% of all depressed patients.13 Future studies could use a match-mismatch 
design in which patients with and without low-grade inflammation are allocated to 
‘matched’ and ‘mismatched’ treatment modalities. We would expect patients with higher 
levels of inflammation to respond better to ECT and patients with lower inflammation to 
respond better to antidepressants. 
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Moreover, a meta-analysis of Kohler et al.98 showed that both add-on therapy and 
monotherapy with anti-inflammatory medication can reduce depressive symptoms. 
Most effective were add-on NSAIDs, monotherapy cytokine inhibitors, add-on 
glucocorticoids, and add-on or monotherapy minocycline, although studies are 
heterogeneous and small. Almost all studies up to date have included a heterogeneous 
group of depressed patients. As approximately one-third of patients have increased 
inflammation13, studies should target those patients specifically. Further research could 
be in the form of large randomized controlled trials in which depressed patients with 
increased inflammation are allocated to several anti-inflammatory medications and 
placebo. Cytokine-inhibitors such as Tocilizumab (anti-IL-6), Siltuximab (anti-IL-6), and 
Adalimumab (anti-TNF-α) could be useful as they specifically target measurable peripheral 
markers. Outcome measures should not include general depression severity only, but 
also include cytokine associated behavioural symptoms such as symptoms of anhedonia 
and anxiety.99–101 It is also important to monitor adverse events of anti-inflammatory 
medication, especially in older persons. 
Furthermore, our results suggest that patients with depression with higher levels of 
inflammatory markers experience lower cognitive functioning. Further research is 
needed to explore whether reducing inflammation can increase cognitive functioning 
in depression and ECT. Future studies should focus on the effect of anti-inflammatory 
treatment on cognitive functioning in depression.
In Chapter 2, we found that patients with low levels of S100B had less favourable 
responses to ECT. S100B is used as a marker of neuroplasticity and has various functions 
in neuroplasticity itself.2 If our findings are confirmed, the next step would be to explore 
treatment strategies that may increase the level of S100B and whether this contributes 
to responsiveness to depression treatment. From a biological perspective, there is a link 
between inflammation and neuroplasticity. For example, peripheral inflammation can 
activate microglia who in their turn promote the release of cytokines.12 How both these 
processes are involved in depression needs further investigation. 
Finally, the working mechanism of ECT remains unclear. In Chapter 3 we were unable 
to confirm an anti-inflammatory effect of ECT. So why do patients with higher levels of 
inflammation and S100B respond better to ECT in particular? The hypothesis that ECT 
activates microglia cells by inducing an acute immune response should be tested in 
clinical samples of depressed patients with the use of PET scans that can measure 
microglia activation and blood samples measuring immune activation. 
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Concluding remarks
The main message that can be drawn from this thesis is that inflammatory processes 
seem to be involved in both cognitive functioning and response to treatment and that 
ECT is effective in treating patients with increased levels of inflammatory markers. 
However, as anti-inflammatory properties of ECT could not be confirmed, other 
antidepressant treatment modalities that fall outside the scope of this thesis may be 
even more effective. Inflammatory biomarkers can aid in future personalized depression 
treatment perhaps by implementing stratified care instead of stepped care. For example, if 
findings are confirmed, ECT could be started in patients with higher levels of inflammation 
before starting second or third trials with antidepressant medication. Inflammatory 
biomarkers may also be useful in developing new antidepressant treatment strategies 
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Dit proefschrift had als doel de huidige kennis over biomarkers en elektroconvulsie 
therapie (ECT) te vergroten en zo bij te dragen aan toekomstige gepersonaliseerde 
behandeling van depressie op oudere leeftijd, met name bij patiënten die met ECT worden 
behandeld. Het eerste deel van dit werk onderzocht het patroon van biologische markers 
tijdens ECT en de associatie tussen biologische markers en uitkomst van behandeling. Het 
tweede deel onderzocht de associatie tussen biomarkers, cognitief functioneren en witte stof 
hyperintensiteiten. In de afgelopen 30 jaar zijn er meer dan 8000 onderzoeken naar ECT 
uitgevoerd en ondanks al die studies kunnen we op dit moment niet onderscheiden 
welke patiënten het beste zullen reageren op antidepressiva en welke op ECT. Er wordt 
gebruik gemaakt van een stapsgewijs behandelprotocol dat voor alle depressieve 
patiënten gelijk is. ECT wordt pas aanbevolen bij patiënten die onvoldoende opgeknapt 
zijn op ten minste twee antidepressieve medicamenten. In dit proefschrift onderzochten 
we of biologische markers kunnen helpen in het onderscheid welke patiënten zullen 
verbeteren op ECT (Deel I) en wie er meer kans hebben op cognitieve bijwerkingen 




Een van de biomarkers die we onderzocht hebben is het calciumbindende eiwit 
S100 (S100B). S100B is een eiwit dat tot expressie wordt gebracht door microgliacellen 
(astrocyten en oligodendrocyten) en dat verschillende functies heeft bij neuronale 
plasticiteit en apoptose. Het kan onder andere worden gebruikt als een marker van 
neuroplasticiteit. In toenemende mate wordt gedacht dat neuroplasticiteit verstoord 
is bij depressie en uit meerdere studies blijkt dat depressieve patiënten hogere 
S100B-waarden hebben dan gezonde controles. Ook wordt neuroplasticiteit beschouwd 
als een mogelijk onderdeel van het werkingsmechanisme van ECT doordat is aangetoond 
dat het volume van de hippocampus, amygdala en cingulaire cortex toenemen na ECT. 
In Hoofdstuk 2 onderzochten we of S100B een marker was voor de aanwezigheid van 
depressie en of S100B geassocieerd was met een gunstige ECT-uitkomst binnen het 
MODECT-cohort van 110 oudere depressieve patiënten die allemaal met ECT behandeld 
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werden. Veranderingen in S100B-waarden voor- en na ECT werden vergeleken tussen 
patiënten die van hun depressie herstelden (remitters) en patiënten die niet herstelden 
(niet-remitters). Er was geen significante afname in S100B-waarden na ECT bij zowel 
remitters als niet-remitters, waardoor het minder waarschijnlijk is dat S100B een 
marker is die depressie aantoont. Patiënten met S100B waarden tussen 33 ng/L en 
53 ng/L vóór ECT hadden een gunstiger behandelresultaat vergeleken met patiënten 
met lagere of hogere waarden van S100B. Ze hadden ook meer kans om na verloop van 
tijd van hun depressie te herstellen. Ondanks de associatie tussen S100B en remissie, 
waren de sensitiviteit en specificiteit laag, daarom wordt S100B niet beschouwd als een 
geschikte biomarker voor ECT-uitkomst.
Inflammatie
Andere biomarkers die centraal stonden in dit proefschrift waren de inflammatoire 
markers; C-reactief proteïne (CRP), interleukine-6 (IL-6), interleukine-10 (IL-10) en 
tumornecrosefactor-alfa (TNF-α). Deze markers kunnen de bloed-hersenbarrière 
passeren en daar vervolgens (door activatie van microglia) zowel neuro-inflammatie als 
neuroplasticiteit beïnvloeden. Depressie en ontsteking worden de laatste jaren veelvuldig 
met elkaar in verband gebracht. Ten eerste worden er bij patiënten met depressie 
hogere inflammatoire markers gevonden dan in gezonde controlepersonen. In de groep 
patiënten met een depressie op latere leeftijd blijkt dit bij bijna de helft van de patiënten 
het geval. Ten tweede wordt gesuggereerd dat inflammatoire markers een rol spelen in 
de pathofysiologie van depressie. Ten derde lijkt er een verband te zijn tussen perifeer 
aanwezige inflammatoire markers en behandelrespons of non-respons.
In Hoofdstuk 3 hebben we onderzocht of er een verband bestond tussen de hoogte van 
inflammatoire markers vooraf aan de behandeling met ECT en de behandelrespons. We 
zagen dat matig verhoogde waarden (3 tot 10 mg/L; laaggradige inflammatie) van CRP 
geassocieerd waren met hogere remissiecijfers van depressie en een snellere 
symptoomafname tijdens ECT. Er werd een remissiepercentage van 83,9% gevonden bij 
patiënten met een CRP van 3 tot 10 mg/L, vergeleken met een remissiepercentage van 
61,1% bij patiënten met een CRP-spiegel lager dan 3 mg/L. Per ECT-toediening schatten 
we een afname van 3,2 MADRS-punten (Montgomery Åsberg Depression Rating 
Scale) in de matig verhoogde CRP-groep vergeleken met 2,3 MADRS-punten in de lage 
CRP-groep. Er werden geen consistente associaties gevonden tussen IL-6, IL-10, TNF-α en 
behandelrespons. We concludeerden dat oudere depressieve patiënten met laaggradige 
inflammatie meer baat hebben bij ECT dan patiënten zonder laaggradige inflammatie.
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Vervolgens wilden we onderzoeken of ECT een ontstekingsremmend effect heeft. 
Eerdere studies vonden een toename van leukocyten, interleukine-1 en IL-6 na één 
enkele ECT-toediening passend bij een acute immuunreactie. Na herhaalde ECT-toedie-
ningen, hoewel het aantal onderzoeken beperkt was, leken interleukine-5, IL-6 en TNF-α 
juist te dalen. Om te onderzoeken of ECT een ontstekingsremmende werking heeft, 
onderzochten we het patroon van CRP, IL-6, IL-10 en TNF-α tijdens en na ECT (Hoofdstuk 4). 
We vonden kleine tot middelgrote effectgroottes voor een afname van CRP en IL-6 na ECT. 
Er werden geen verschillen gevonden in het patroon van inflammatoire markers tussen 
responders en non-responders, en tussen remitters en non-remitters van depressie. 
We concludeerden dat een mogelijke afname van inflammatoire markers na ECT niet 
geassocieerd is met behandelrespons en dat het ontstekingsremmende effect van ECT 
niet kon worden aangetoond in deze studie.
Apathie
Depressie op latere leeftijd is in verband gebracht met veranderingen in witte hersenstof 
en veranderingen in witte hersenstof zijn op hun beurt in verband gebracht met apathie. 
Ondanks dat er een overlap bestaat tussen motivationele symptomen van depressie en 
apathische symptomen, wordt apathie beschouwd als een onafhankelijk syndroom. Van 
apathie is bekend dat het de kwaliteit van leven verlaagd. In Hoofdstuk 5 hebben we 
onderzocht of er een verband was tussen vasculaire belasting en het beloop van apathie 
bij 73 apathische patiënten die met ECT werden behandeld binnen het MODECT-cohort. 
Vasculaire belasting omvatte de aanwezigheid van vaatziekte, diabetes mellitus, roken 
en hyperintensiteit van witte stof. MRI-gegevens over witte stof hyperintensiteiten waren 
beschikbaar bij 52/73 patiënten. Na ECT waren 50 patiënten (68,5%) hersteld van hun 
depressie. Van deze 50 patiënten leed 52,0% nog aan apathie. Van de patiënten 
die niet herstelden van hun depressie (n = 23) ervoer 78,3% apathie. Er werd geen 
verband gevonden tussen aanhoudende apathie en vasculaire belasting. Ten eerste 
concludeerden we dat een succesvolle ECT behandeling niet altijd gepaard gaat met een 
afname van apathie en dat de behandeling van apathie mogelijk een andere aanpak 
vereist. Ten tweede was het mogelijk dat de aanhoudende apathiesymptomen in ons 
cohort restsymptomen waren van depressie. Tot slot leek het erop dat apathie bij 
depressieve patiënten verschilt van apathie bij niet-depressieve patiënten omdat 
wij in tegenstelling tot vele andere studies geen associatie vonden tussen apathie en 
vasculaire belasting. Dit idee wordt versterkt door studies waarbij een sterk verband 
wordt gevonden tussen hoge CRP-waarden en apathie bij niet-depressieve patiënten, 
maar geen verband bij depressieve patiënten.
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DEEL II:
Biomarkers en cognitie
Om dichter bij een gepersonaliseerde depressie behandeling te komen is het, naast 
het onderzoeken van de behandelrespons, ook belangrijk om onderzoek te doen naar 
de bijwerkingen van ECT. Voor veel betrokkenen, zowel patiënten, hun naasten en 
behandelaars blijven cognitieve bijwerkingen na ECT een punt van zorg. In Hoofdstuk 6 
onderzochten we of inflammatoire markers ons konden helpen identificeren welke 
patiënten meer vatbaar zijn voor het ontwikkelen van cognitieve bijwerkingen tijdens 
en na ECT. Het cognitief functioneren werd beoordeeld met de Mini-Mental State 
Examination (MMSE). Ontstekingswaarden vooraf aan de behandeling bleken 
geassocieerd met een verminderd cognitief functioneren voorafgaand aan ECT (TNF-α). 
Omdat deze associatie aanwezig was vóór de start van ECT, konden we de additionele 
invloed van ECT op deze associatie niet goed ontwarren. Een bekende risicofactor voor 
een lager cognitief functioneren tijdens en na ECT is een slecht cognitief functioneren op 
baseline. Dit is in lijn met onze bevindingen. Ook vonden eerdere studies een verband 
tussen cognitieve stoornissen en hogere ontstekingswaarden bij oudere, gezonde of 
depressieve proefpersonen. We denken dat vergelijkbare processen betrokken zijn bij 
cognitief functioneren tijdens ECT, dat wil zeggen, dat een lager cognitief functioneren 
vooraf aan ECT geassocieerd is met hogere ontstekingswaarden. Deze patiënten zijn 
vervolgens vatbaar voor cognitieve disfunctie tijdens en na ECT, hoewel het toe te 
schrijven effect van ECT onzeker blijft.
Naast het verband tussen inflammatie en cognitie, komt in meerdere studies naar voren 
dat er ook een verband bestaat tussen lager cognitief functioneren, depressie en witte stof 
hyperintensiteiten. Daarom hebben we in Hoofdstuk 7 onderzocht of de aanwezigheid 
van hyperintensiteiten in witte stof de gevonden associatie in Hoofdstuk 6 (tussen 
inflammatoire markers en cognitief functioneren) versterkt. Om de invloed van ECT te 
onderzoeken hebben we voor deze analyse gekeken naar het cognitief functioneren na 
ECT. Het verband tussen hogere waarden van IL-10 en TNF-α vooraf aan ECT en een 
lager cognitief functioneren na ECT werd alleen gevonden bij patiënten mét witte stof 
hyperintensiteiten. We concludeerden dat patiënten met witte stof hyperintensiteiten 




Het doel van dit proefschrift was het vergroten van de kennis over biomarkers en 
elektroconvulsie therapie (ECT) en zo bij te dragen aan toekomstige gepersonaliseerde 
behandeling van depressie op oudere leeftijd. In dit proefschrift onderzochten we onder 
andere C-reactief proteïne (CRP), als inflammatie-marker, en calciumbindend eiwit 
S100 (S100B), als neurotrofine. De belangrijkste boodschap die uit dit proefschrift 
getrokken kan worden, is dat ontstekingsprocessen betrokken lijken te zijn bij zowel 
het cognitief functioneren tijdens een depressie als de uitkomst van ECT. Oudere 
depressieve patiënten met laaggradige inflammatie of intermediaire S100B-waarden 
die behandeld worden met ECT, hebben een grotere kans op herstel van depressie. We 
concluderen echter ook dat zowel CRP als S100B op zichzelf onvoldoende sensitiviteit en 
specificiteit hebben om ECT-uitkomst te kunnen voorspellen. Van bruikbare biomarkers 
wordt verwacht dat ze een sensitiviteit (voor het detecteren van ECT-uitkomst) en een 
specificiteit (voor het discrimineren tussen uitkomsten) hebben van ten minste 80%. De 
eventuele ontstekingsremmende werking van ECT kon in dit proefschrift niet worden 
bevestigd. Het kan dus zijn dat andere depressiebehandelingen - die buiten het bestek 
van dit proefschrift vallen - nog effectiever zijn bij patiënten met laaggradige inflammatie 
dan ECT. 
Concluderend kan gesteld worden dat biomarkers kunnen bijdragen aan toekomstige 
gepersonaliseerde behandeling voor depressie. In de huidige richtlijn wordt een 
‘stepped-care’ benadering gevolgd waarbij patiënten eerst lichte interventies krijgen en 
bij onvoldoende herstel zwaardere interventies. Een alternatief zou kunnen zijn om bij 
depressie voor ‘stratified-care’ te kiezen waarbij de behandeling wordt afgestemd op de 
kenmerken van de patiënt. Als onze bevindingen worden bevestigd zou bijvoorbeeld een 
patiënt met laaggradige inflammatie eerder in aanmerking komen voor ECT dan in het 
huidige model. Ook zou toekomstig onderzoek zich kunnen richten op strategieën om 
depressie te behandelen en het cognitief functioneren te verbeteren door bijvoorbeeld 
additioneel te behandelen met ontstekingsremmende medicatie. 
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